beta

GBT

Global Blood Therapeutics Inc.

Gbt

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-26-2019 02-25-2019 02-25-2019 02-25-2019 02-25-2019 02-25-2019 02-25-2019 02-25-2019 02-25-2019 02-25-2019 02-25-2019 02-25-2019 02-25-2019 02-25-2019 02-25-2019 02-25-2019 02-25-2019 02-25-2019 02-25-2019 11-06-2018 08-02-2018 05-07-2018 02-27-2018 11-02-2017 08-07-2017 05-01-2017
Actual EPS -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.93 -0.83 -0.78 -0.87 -0.94 -0.66 -0.55 -0.6
Consensus EPS -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.84 -0.87 -0.92 -0.71 -0.61 -0.6 -0.7
Estimated EPS -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.84 -0.87 -0.92 -0.71 -0.61 -0.6 -0.7
Number of Estimates 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 9 10 10 7 7 7
EPS Surprise -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 -$0.05 $0.01 $0.09 $0.05 -$0.23 -$0.05 $0.05 $0.10

Stats

Summary

Global Blood Therapeutics Inc is a clinical-stage biopharmaceutical company in the United States. Its major focus lies on developing therapeutics for the treatment of blood-based disorders such as red blood cell sickling.

Market Cap: 2.8 Billion

Primary Exchange: Nasdaq Global Select

Website: http://www.globalbloodtx.com

Shares Outstanding: 46.3 Million

Float: 44.6 Million

Dividend: 0.0 (0.0%)

Beta: 4.916987

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 5.35 Million

Ethical Flags

Animal testing

Longest drawdown: 538 trading days

From: 2015-11-18 To: 2018-01-09

Lowest Point:

Chewy IPO, Lululemon And Tesla On Tap (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-06-09 03:30:00:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks.. If you are interested in listening to Stocks To Watch to start your Sunday (you can r… read more...

Chewy IPO, Lululemon And Tesla On Tap (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-06-09 03:30:00:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks.. If you are interested in listening to Stocks To Watch to start your Sunday (you can r… read more...

Chewy IPO, Lululemon And Tesla On Tap (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-06-09 03:30:00:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks.. If you are interested in listening to Stocks To Watch to start your Sunday (you can r… read more...

Stocks To Watch: Chewy IPO, Lululemon And Tesla On Tap

via: SeekingAlpha at 2019-06-08 03:55:43:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes… read more...

American Society Of Clinical Oncology: A Biotech Friendly Event In An Unfriendly Healthcare Market

via: SeekingAlpha at 2019-06-02 12:56:36:000

Market Pulse The month of May thus far has been mostly a downward ride with an occasional rise, proving to be a mere bunny bump, as indexes have eroded persistently on the lack of a trade resolution with China, an outcome that at one point was considered to be almost in the bag. This is rais… read more...

American Society Of Clinical Oncology: A Biotech Friendly Event In An Unfriendly Healthcare Market

via: SeekingAlpha at 2019-06-02 12:56:36:000

Market Pulse The month of May thus far has been mostly a downward ride with an occasional rise, proving to be a mere bunny bump, as indexes have eroded persistently on the lack of a trade resolution with China, an outcome that at one point was considered to be almost in the bag. This is rais… read more...

American Society Of Clinical Oncology: A Biotech Friendly Event In An Unfriendly Healthcare Market

via: SeekingAlpha at 2019-06-02 12:56:36:000

Market Pulse The month of May thus far has been mostly a downward ride with an occasional rise, proving to be a mere bunny bump, as indexes have eroded persistently on the lack of a trade resolution with China, an outcome that at one point was considered to be almost in the bag. This is rais… read more...

High Short Interest, Strong Performance Stocks: May 2019

via: SeekingAlpha at 2019-05-22 06:18:08:000

Higher short interest is an odd indicator in the market. On one hand, it's a good indicator of sentiment as a high level generally suggests skepticism of the company's outlook, bringing bears to expect eventually lower share prices. It's also a poor indicator because significant levels of shor… read more...

High Short Interest, Strong Performance Stocks: May 2019

via: SeekingAlpha at 2019-05-22 06:18:08:000

Higher short interest is an odd indicator in the market. On one hand, it's a good indicator of sentiment as a high level generally suggests skepticism of the company's outlook, bringing bears to expect eventually lower share prices. It's also a poor indicator because significant levels of shor… read more...

High Short Interest, Strong Performance Stocks: May 2019

via: SeekingAlpha at 2019-05-22 06:18:08:000

Higher short interest is an odd indicator in the market. On one hand, it's a good indicator of sentiment as a high level generally suggests skepticism of the company's outlook, bringing bears to expect eventually lower share prices. It's also a poor indicator because significant levels of shor… read more...

High Short Interest, Strong Performance Stocks: May 2019

via: SeekingAlpha at 2019-05-22 06:18:08:000

Higher short interest is an odd indicator in the market. On one hand, it's a good indicator of sentiment as a high level generally suggests skepticism of the company's outlook, bringing bears to expect eventually lower share prices. It's also a poor indicator because significant levels of shor… read more...

High Short Interest, Strong Performance Stocks: May 2019

via: SeekingAlpha at 2019-05-22 06:18:08:000

Higher short interest is an odd indicator in the market. On one hand, it's a good indicator of sentiment as a high level generally suggests skepticism of the company's outlook, bringing bears to expect eventually lower share prices. It's also a poor indicator because significant levels of shor… read more...

High Short Interest, Strong Performance Stocks: May 2019

via: SeekingAlpha at 2019-05-22 06:18:08:000

Higher short interest is an odd indicator in the market. On one hand, it's a good indicator of sentiment as a high level generally suggests skepticism of the company's outlook, bringing bears to expect eventually lower share prices. It's also a poor indicator because significant levels of shor… read more...

3 Gene Therapy Stocks For A Biotech Portfolio

via: SeekingAlpha at 2019-05-20 08:53:25:000

Biotech Pulse The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have struggled since March as the broader healthcare sector ( XLV ) declined following growing momentum amongst the presidential candidates for a universal healthcare plan. This was at a time when the broader ma… read more...

3 Gene Therapy Stocks For A Biotech Portfolio

via: SeekingAlpha at 2019-05-20 08:53:25:000

Biotech Pulse The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have struggled since March as the broader healthcare sector ( XLV ) declined following growing momentum amongst the presidential candidates for a universal healthcare plan. This was at a time when the broader ma… read more...

Global Blood Remains On Track For Transformational Year

via: SeekingAlpha at 2019-05-15 05:30:07:000

Capital Structure Idea Slides Chart GBT's 50MA has served as key support throughout 2019 and the recent dip appears to allow investors another advantageous buying point. Introduction Global Blood Therapeutics ( GBT ) remains a top conviction pick in 2Q 2019, as the compa… read more...

Global Blood Remains On Track For Transformational Year

via: SeekingAlpha at 2019-05-15 05:30:07:000

Capital Structure Idea Slides Chart GBT's 50MA has served as key support throughout 2019 and the recent dip appears to allow investors another advantageous buying point. Introduction Global Blood Therapeutics ( GBT ) remains a top conviction pick in 2Q 2019, as the compa… read more...

Global Blood Remains On Track For Transformational Year

via: SeekingAlpha at 2019-05-15 05:30:07:000

Capital Structure Idea Slides Chart GBT's 50MA has served as key support throughout 2019 and the recent dip appears to allow investors another advantageous buying point. Introduction Global Blood Therapeutics ( GBT ) remains a top conviction pick in 2Q 2019, as the compa… read more...

Global Blood Therapeutics beats by $0.06

via: SeekingAlpha at 2019-05-08 12:53:19:000

Global Blood Therapeutics (NASDAQ: GBT ): Q1 GAAP EPS of -$0.87 beats by $0.06. More news on: Global Blood Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Global Blood Therapeutics beats by $0.06

via: SeekingAlpha at 2019-05-08 12:53:19:000

Global Blood Therapeutics (NASDAQ: GBT ): Q1 GAAP EPS of -$0.87 beats by $0.06. More news on: Global Blood Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Global Blood Therapeutics beats by $0.06

via: SeekingAlpha at 2019-05-08 12:53:19:000

Global Blood Therapeutics (NASDAQ: GBT ): Q1 GAAP EPS of -$0.87 beats by $0.06. More news on: Global Blood Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Market At New Highs, But Healthcare And Biotechs Feel The Heat

via: SeekingAlpha at 2019-04-29 09:22:32:000

Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m… read more...

Market At New Highs, But Healthcare And Biotechs Feel The Heat

via: SeekingAlpha at 2019-04-29 09:22:32:000

Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m… read more...

Market At New Highs, But Healthcare And Biotechs Feel The Heat

via: SeekingAlpha at 2019-04-29 09:22:32:000

Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m… read more...

Market At New Highs, But Healthcare And Biotechs Feel The Heat

via: SeekingAlpha at 2019-04-29 09:22:32:000

Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m… read more...

Market At New Highs, But Healthcare And Biotechs Feel The Heat

via: SeekingAlpha at 2019-04-29 09:22:32:000

Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m… read more...

Managing Biotech Investing Risk With Jonathan Faison (Podcast)

via: SeekingAlpha at 2019-04-10 03:00:00:000

By Jonathan Liss Listen and subscribe to the Marketplace Roundtable on these podcast platforms: iTunes/Apple Podcasts Spotify Stitcher Jonathan Faison doesn't want prospective biotech investors to think that they need some sort of "special sauce" to succeed… read more...

Managing Biotech Investing Risk With Jonathan Faison (Podcast)

via: SeekingAlpha at 2019-04-10 03:00:00:000

By Jonathan Liss Listen and subscribe to the Marketplace Roundtable on these podcast platforms: iTunes/Apple Podcasts Spotify Stitcher Jonathan Faison doesn't want prospective biotech investors to think that they need some sort of "special sauce" to succeed… read more...

Managing Biotech Investing Risk With Jonathan Faison (Podcast)

via: SeekingAlpha at 2019-04-10 03:00:00:000

By Jonathan Liss Listen and subscribe to the Marketplace Roundtable on these podcast platforms: iTunes/Apple Podcasts Spotify Stitcher Jonathan Faison doesn't want prospective biotech investors to think that they need some sort of "special sauce" to succeed… read more...

Healthcare Breakout Beat 2018 Forecast: How High Will It Go In 2019?

via: SeekingAlpha at 2019-04-05 07:28:20:000

From the Big Picture to Individual Stock Breakouts Last year I highlighted the Healthcare Biotech Sector Breakout and correctly forecasted "at least 20% gains in sector ETFs and even higher for many key biotech stocks in the near term." I believe the technical analysis that I will det… read more...

Healthcare Breakout Beat 2018 Forecast: How High Will It Go In 2019?

via: SeekingAlpha at 2019-04-05 07:28:20:000

From the Big Picture to Individual Stock Breakouts Last year I highlighted the Healthcare Biotech Sector Breakout and correctly forecasted "at least 20% gains in sector ETFs and even higher for many key biotech stocks in the near term." I believe the technical analysis that I will det… read more...

Healthcare Breakout Beat 2018 Forecast: How High Will It Go In 2019?

via: SeekingAlpha at 2019-04-05 07:28:20:000

From the Big Picture to Individual Stock Breakouts Last year I highlighted the Healthcare Biotech Sector Breakout and correctly forecasted "at least 20% gains in sector ETFs and even higher for many key biotech stocks in the near term." I believe the technical analysis that I will det… read more...

Healthcare Breakout Beat 2018 Forecast: How High Will It Go In 2019?

via: SeekingAlpha at 2019-04-05 07:28:20:000

From the Big Picture to Individual Stock Breakouts Last year I highlighted the Healthcare Biotech Sector Breakout and correctly forecasted "at least 20% gains in sector ETFs and even higher for many key biotech stocks in the near term." I believe the technical analysis that I will det… read more...

Healthcare Breakout Beat 2018 Forecast: How High Will It Go In 2019?

via: SeekingAlpha at 2019-04-05 07:28:20:000

From the Big Picture to Individual Stock Breakouts Last year I highlighted the Healthcare Biotech Sector Breakout and correctly forecasted "at least 20% gains in sector ETFs and even higher for many key biotech stocks in the near term." I believe the technical analysis that I will det… read more...

GlycoMimetics: Forecasting The Clinical Binary For Rivipansel

via: SeekingAlpha at 2019-03-29 14:41:25:000

Never lose money. Stay rational and stick to your homework when researching businesses in which to invest. - Warren Buffett As I appreciate the intellectual curiosity of Integrated BioSci Investing members, I'd like to share with you my analysis of the latest stock tip, GlycoMimetics ( GLY… read more...

GlycoMimetics: Forecasting The Clinical Binary For Rivipansel

via: SeekingAlpha at 2019-03-29 14:41:25:000

Never lose money. Stay rational and stick to your homework when researching businesses in which to invest. - Warren Buffett As I appreciate the intellectual curiosity of Integrated BioSci Investing members, I'd like to share with you my analysis of the latest stock tip, GlycoMimetics ( GLY… read more...

GlycoMimetics: Forecasting The Clinical Binary For Rivipansel

via: SeekingAlpha at 2019-03-29 14:41:25:000

Never lose money. Stay rational and stick to your homework when researching businesses in which to invest. - Warren Buffett As I appreciate the intellectual curiosity of Integrated BioSci Investing members, I'd like to share with you my analysis of the latest stock tip, GlycoMimetics ( GLY… read more...

GlycoMimetics: Forecasting The Clinical Binary For Rivipansel

via: SeekingAlpha at 2019-03-29 14:41:25:000

Never lose money. Stay rational and stick to your homework when researching businesses in which to invest. - Warren Buffett As I appreciate the intellectual curiosity of Integrated BioSci Investing members, I'd like to share with you my analysis of the latest stock tip, GlycoMimetics ( GLY… read more...

GlycoMimetics: Forecasting The Clinical Binary For Rivipansel

via: SeekingAlpha at 2019-03-29 14:41:25:000

Never lose money. Stay rational and stick to your homework when researching businesses in which to invest. - Warren Buffett As I appreciate the intellectual curiosity of Integrated BioSci Investing members, I'd like to share with you my analysis of the latest stock tip, GlycoMimetics ( GLY… read more...

GlycoMimetics: Forecasting The Clinical Binary For Rivipansel

via: SeekingAlpha at 2019-03-29 14:41:25:000

Never lose money. Stay rational and stick to your homework when researching businesses in which to invest. - Warren Buffett As I appreciate the intellectual curiosity of Integrated BioSci Investing members, I'd like to share with you my analysis of the latest stock tip, GlycoMimetics ( GLY… read more...

Guerbet Announces Transition from Temporary Importation to Regular Supply for Lipiodol® (ethiodized oil) Injection; also introduces new glass vial container

via: PR Newswire at 2019-03-25 08:49:00:000

PRINCETON, N.J. , March 25, 2019 /PRNewswire/ --Guerbet LLC USA , the U.S. affiliate of the global specialist in contrast media products and solutions for diagnostic and interventional imaging, today announced the end of temporary importationstatusforLipiodol&#xAE… read more...

Guerbet Announces Transition from Temporary Importation to Regular Supply for Lipiodol® (ethiodized oil) Injection; also introduces new glass vial container

via: PR Newswire at 2019-03-25 08:49:00:000

PRINCETON, N.J. , March 25, 2019 /PRNewswire/ --Guerbet LLC USA , the U.S. affiliate of the global specialist in contrast media products and solutions for diagnostic and interventional imaging, today announced the end of temporary importationstatusforLipiodol&#xAE… read more...

Guerbet Announces Transition from Temporary Importation to Regular Supply for Lipiodol® (ethiodized oil) Injection; also introduces new glass vial container

via: PR Newswire at 2019-03-25 08:49:00:000

PRINCETON, N.J. , March 25, 2019 /PRNewswire/ --Guerbet LLC USA , the U.S. affiliate of the global specialist in contrast media products and solutions for diagnostic and interventional imaging, today announced the end of temporary importationstatusforLipiodol&#xAE… read more...

Guerbet Announces Transition from Temporary Importation to Regular Supply for Lipiodol® (ethiodized oil) Injection; also introduces new glass vial container

via: PR Newswire at 2019-03-25 08:49:00:000

PRINCETON, N.J. , March 25, 2019 /PRNewswire/ --Guerbet LLC USA , the U.S. affiliate of the global specialist in contrast media products and solutions for diagnostic and interventional imaging, today announced the end of temporary importationstatusforLipiodol&#xAE… read more...

Global Blood Therapeutics misses by $0.04

via: SeekingAlpha at 2019-02-27 16:43:04:000

Global Blood Therapeutics (NASDAQ: GBT ): Q4 GAAP EPS of -$0.93 misses by $0.04. More news on: Global Blood Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Global Blood Therapeutics misses by $0.04

via: SeekingAlpha at 2019-02-27 16:43:04:000

Global Blood Therapeutics (NASDAQ: GBT ): Q4 GAAP EPS of -$0.93 misses by $0.04. More news on: Global Blood Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Global Blood Therapeutics misses by $0.04

via: SeekingAlpha at 2019-02-27 11:43:04:000

Global Blood Therapeutics (NASDAQ: GBT ): Q4 GAAP EPS of -$0.93 misses by $0.04. More news on: Global Blood Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Global Blood Therapeutics misses by $0.04

via: SeekingAlpha at 2019-02-27 11:43:04:000

Global Blood Therapeutics (NASDAQ: GBT ): Q4 GAAP EPS of -$0.93 misses by $0.04. More news on: Global Blood Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Biotech Bonanza: The Mergers And Acquisitions Theme

via: SeekingAlpha at 2019-02-13 14:55:11:000

Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an… read more...

Biotech Bonanza: The Mergers And Acquisitions Theme

via: SeekingAlpha at 2019-02-13 14:55:11:000

Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an… read more...

Biotech Bonanza: The Mergers And Acquisitions Theme

via: SeekingAlpha at 2019-02-13 14:55:11:000

Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an… read more...

Biotech Bonanza: The Mergers And Acquisitions Theme

via: SeekingAlpha at 2019-02-13 14:55:11:000

Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an… read more...

Global Blood Therapeutics: A Crucial Year Ahead

via: SeekingAlpha at 2019-02-08 11:52:53:000

"Waste your money and you're only out of money, but waste your time and you've lost a part of your life." - Michael LeBoeuf It has been awhile since we looked in on the progress of developmental concern Global Blood Therapeutics ( GBT ) . A Biotech Forum member requested we revisit this n… read more...

Global Blood Therapeutics: A Crucial Year Ahead

via: SeekingAlpha at 2019-02-08 11:52:53:000

"Waste your money and you're only out of money, but waste your time and you've lost a part of your life." - Michael LeBoeuf It has been awhile since we looked in on the progress of developmental concern Global Blood Therapeutics ( GBT ) . A Biotech Forum member requested we revisit this n… read more...

Global Blood Therapeutics: A Crucial Year Ahead

via: SeekingAlpha at 2019-02-08 11:52:53:000

"Waste your money and you're only out of money, but waste your time and you've lost a part of your life." - Michael LeBoeuf It has been awhile since we looked in on the progress of developmental concern Global Blood Therapeutics ( GBT ) . A Biotech Forum member requested we revisit this n… read more...

Global Blood Therapeutics: A Crucial Year Ahead

via: SeekingAlpha at 2019-02-08 11:52:53:000

"Waste your money and you're only out of money, but waste your time and you've lost a part of your life." - Michael LeBoeuf It has been awhile since we looked in on the progress of developmental concern Global Blood Therapeutics ( GBT ) . A Biotech Forum member requested we revisit this n… read more...

Global Blood Therapeutics: A Crucial Year Ahead

via: SeekingAlpha at 2019-02-08 11:52:53:000

"Waste your money and you're only out of money, but waste your time and you've lost a part of your life." - Michael LeBoeuf It has been awhile since we looked in on the progress of developmental concern Global Blood Therapeutics ( GBT ) . A Biotech Forum member requested we revisit this n… read more...

Global Blood Therapeutics: Investment Update And New Data Via Passionate-Use

via: SeekingAlpha at 2019-01-28 21:29:29:000

Investment Update Investors of Global Blood Therapeutics ( GBT ) have a lot to look forward to in 2019 and beyond: Management still intends to meet with the FDA in Q1 '19 to discuss details surrounding Voxelotor's path to the market and the confirmatory trial requirements. Voxelotor'… read more...

Global Blood Therapeutics: Investment Update And New Data Via Passionate-Use

via: SeekingAlpha at 2019-01-28 21:29:29:000

Investment Update Investors of Global Blood Therapeutics ( GBT ) have a lot to look forward to in 2019 and beyond: Management still intends to meet with the FDA in Q1 '19 to discuss details surrounding Voxelotor's path to the market and the confirmatory trial requirements. Voxelotor'… read more...

Global Blood Therapeutics: Investment Update And New Data Via Passionate-Use

via: SeekingAlpha at 2019-01-28 21:29:29:000

Investment Update Investors of Global Blood Therapeutics ( GBT ) have a lot to look forward to in 2019 and beyond: Management still intends to meet with the FDA in Q1 '19 to discuss details surrounding Voxelotor's path to the market and the confirmatory trial requirements. Voxelotor'… read more...

Citi cuts CRISPR Therapeutics to Sell, shares down 7% premarket

via: SeekingAlpha at 2019-01-22 07:48:56:000

CRISPR Therapeutics (NASDAQ: CRSP ) is off 7% premarket on light volume on the heels of a downgrade to Sell with a $21 (43% downside risk) price target at Citigroup. More news on: CRISPR Therapeutics, bluebird bio, Inc., Global Blood Therapeutics, Healthcare stocks news, Stocks… read more...

Citi cuts CRISPR Therapeutics to Sell, shares down 7% premarket

via: SeekingAlpha at 2019-01-22 07:48:56:000

CRISPR Therapeutics (NASDAQ: CRSP ) is off 7% premarket on light volume on the heels of a downgrade to Sell with a $21 (43% downside risk) price target at Citigroup. More news on: CRISPR Therapeutics, bluebird bio, Inc., Global Blood Therapeutics, Healthcare stocks news, Stocks… read more...

Citi cuts CRISPR Therapeutics to Sell, shares down 7% premarket

via: SeekingAlpha at 2019-01-22 07:48:56:000

CRISPR Therapeutics (NASDAQ: CRSP ) is off 7% premarket on light volume on the heels of a downgrade to Sell with a $21 (43% downside risk) price target at Citigroup. More news on: CRISPR Therapeutics, bluebird bio, Inc., Global Blood Therapeutics, Healthcare stocks news, Stocks… read more...

Novartis' Breakthrough Designation Will Create Quicker Path To FDA Approval

via: SeekingAlpha at 2019-01-15 14:35:40:000

Recently, Novartis ( NVS ) announced that it had received FDA breakthrough Therapy Designation for its sickle cell drug crizanlizumab (SEG101). This drug treats a specific item that occurs in patients with sickle cell disease ((SCD)) known as vaso-occlusive crises ((VOCS)). This is an impo… read more...

Novartis' Breakthrough Designation Will Create Quicker Path To FDA Approval

via: SeekingAlpha at 2019-01-15 14:35:40:000

Recently, Novartis ( NVS ) announced that it had received FDA breakthrough Therapy Designation for its sickle cell drug crizanlizumab (SEG101). This drug treats a specific item that occurs in patients with sickle cell disease ((SCD)) known as vaso-occlusive crises ((VOCS)). This is an impo… read more...

Novartis' Breakthrough Designation Will Create Quicker Path To FDA Approval

via: SeekingAlpha at 2019-01-15 14:35:40:000

Recently, Novartis ( NVS ) announced that it had received FDA breakthrough Therapy Designation for its sickle cell drug crizanlizumab (SEG101). This drug treats a specific item that occurs in patients with sickle cell disease ((SCD)) known as vaso-occlusive crises ((VOCS)). This is an impo… read more...

Global Blood Therapeutics Continues To Build Strong Case For Successful Commercialization

via: SeekingAlpha at 2019-01-14 20:43:58:000

Global Blood Therapeutics' Drug is Effective - No Doubt To refresh investor's memory, Global Blood Therapeutics ( GBT ) released positive data, from a Phase 3 clinical trial, HOPE, evaluating voxelotor in patients at least 12 years old with sickle cell disease. The results were presented at … read more...

Global Blood Therapeutics Continues To Build Strong Case For Successful Commercialization

via: SeekingAlpha at 2019-01-14 20:43:58:000

Global Blood Therapeutics' Drug is Effective - No Doubt To refresh investor's memory, Global Blood Therapeutics ( GBT ) released positive data, from a Phase 3 clinical trial, HOPE, evaluating voxelotor in patients at least 12 years old with sickle cell disease. The results were presented at … read more...

Global Blood Therapeutics Continues To Build Strong Case For Successful Commercialization

via: SeekingAlpha at 2019-01-14 20:43:58:000

Global Blood Therapeutics' Drug is Effective - No Doubt To refresh investor's memory, Global Blood Therapeutics ( GBT ) released positive data, from a Phase 3 clinical trial, HOPE, evaluating voxelotor in patients at least 12 years old with sickle cell disease. The results were presented at … read more...

Global Blood Therapeutics (GBT) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2019-01-10 06:19:31:000

The following slide deck was published by Global Blood Therapeutics in conjunction with this Read more … read more...

Global Blood Therapeutics (GBT) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2019-01-10 06:19:31:000

The following slide deck was published by Global Blood Therapeutics in conjunction with this Read more … read more...

Global Blood Therapeutics (GBT) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2019-01-10 06:19:31:000

The following slide deck was published by Global Blood Therapeutics in conjunction with this Read more … read more...

Global Blood Therapeutics (GBT) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2019-01-10 06:19:31:000

The following slide deck was published by Global Blood Therapeutics in conjunction with this Read more … read more...

CRISPR Therapeutics Is Dead Money For Years To Come

via: SeekingAlpha at 2019-01-03 19:30:48:000

Intro - Risk in Investing CRISPR Therapeutics ( CRSP ) is a leading gene editing company that is focused on translating revolutionary CRISPR/Cas9 technology into transformative therapies. The stock price has fallen significantly in the past 6 months, but this was warranted due to concerns… read more...

CRISPR Therapeutics Is Dead Money For Years To Come

via: SeekingAlpha at 2019-01-03 19:30:48:000

Intro - Risk in Investing CRISPR Therapeutics ( CRSP ) is a leading gene editing company that is focused on translating revolutionary CRISPR/Cas9 technology into transformative therapies. The stock price has fallen significantly in the past 6 months, but this was warranted due to concerns… read more...

CRISPR Therapeutics Is Dead Money For Years To Come

via: SeekingAlpha at 2019-01-03 19:30:48:000

Intro - Risk in Investing CRISPR Therapeutics ( CRSP ) is a leading gene editing company that is focused on translating revolutionary CRISPR/Cas9 technology into transformative therapies. The stock price has fallen significantly in the past 6 months, but this was warranted due to concerns… read more...

CRISPR Therapeutics Is Dead Money For Years To Come

via: SeekingAlpha at 2019-01-03 19:30:48:000

Intro - Risk in Investing CRISPR Therapeutics ( CRSP ) is a leading gene editing company that is focused on translating revolutionary CRISPR/Cas9 technology into transformative therapies. The stock price has fallen significantly in the past 6 months, but this was warranted due to concerns… read more...

CRISPR Therapeutics Is Dead Money For Years To Come

via: SeekingAlpha at 2019-01-03 19:30:48:000

Intro - Risk in Investing CRISPR Therapeutics ( CRSP ) is a leading gene editing company that is focused on translating revolutionary CRISPR/Cas9 technology into transformative therapies. The stock price has fallen significantly in the past 6 months, but this was warranted due to concerns… read more...

2019 Market Outlook - Similarities To 2017, Recession Expectations May Be Misplaced

via: SeekingAlpha at 2019-01-02 10:13:42:000

Introduction In the last twelve months, weve seen investor euphoria peak, replaced by pessimism and calls for a potential recession in 2019. The recent sell-off in U.S. equities during the second half of 2018 we believe was driven by three catalysts; 1) ETF redemptions, and thus se… read more...

2019 Market Outlook - Similarities To 2017, Recession Expectations May Be Misplaced

via: SeekingAlpha at 2019-01-02 10:13:42:000

Introduction In the last twelve months, weve seen investor euphoria peak, replaced by pessimism and calls for a potential recession in 2019. The recent sell-off in U.S. equities during the second half of 2018 we believe was driven by three catalysts; 1) ETF redemptions, and thus se… read more...

An End-Of-The Year Review For Stocks I've Written About In 2018

via: SeekingAlpha at 2018-12-31 04:50:07:000

(Source: Evil Speculator) Anyone thinking 2018 investing hasnt been anything other than a proverbial roller-coaster ride needs their sanity checked. Thankfully, the end of the year is fast approaching, and if given the option to choose - bull or bear - I would have, and did, opt for … read more...

An End-Of-The Year Review For Stocks I've Written About In 2018

via: SeekingAlpha at 2018-12-31 04:50:07:000

(Source: Evil Speculator) Anyone thinking 2018 investing hasnt been anything other than a proverbial roller-coaster ride needs their sanity checked. Thankfully, the end of the year is fast approaching, and if given the option to choose - bull or bear - I would have, and did, opt for … read more...

Keeping Focused Amidst The Biotech Bear

via: SeekingAlpha at 2018-12-28 06:30:00:000

2018 seems to be ending on a bad note in the markets. December is setting the wrong kind of records, and Q4 has been a bumpy one in general. This is what happens in the stock market sometimes, but it's been easy to forget over the decade-long bull market. We're using the end of the year as a… read more...

Keeping Focused Amidst The Biotech Bear

via: SeekingAlpha at 2018-12-28 06:30:00:000

2018 seems to be ending on a bad note in the markets. December is setting the wrong kind of records, and Q4 has been a bumpy one in general. This is what happens in the stock market sometimes, but it's been easy to forget over the decade-long bull market. We're using the end of the year as a… read more...

Keeping Focused Amidst The Biotech Bear

via: SeekingAlpha at 2018-12-28 06:30:00:000

2018 seems to be ending on a bad note in the markets. December is setting the wrong kind of records, and Q4 has been a bumpy one in general. This is what happens in the stock market sometimes, but it's been easy to forget over the decade-long bull market. We're using the end of the year as a… read more...

Biotech Bonanza: 2019 Outlook On An Uphill Battle

via: SeekingAlpha at 2018-12-20 14:47:33:000

Biotech Pulse The stock market was on track for a solid double-digit return performance in 2018, until it entered the final quarter. The performance cart has been rattling ever since as the stock market's perception of risk has risen dramatically, leading to a sharp erosion of returns. While… read more...

Biotech Bonanza: 2019 Outlook On An Uphill Battle

via: SeekingAlpha at 2018-12-20 14:47:33:000

Biotech Pulse The stock market was on track for a solid double-digit return performance in 2018, until it entered the final quarter. The performance cart has been rattling ever since as the stock market's perception of risk has risen dramatically, leading to a sharp erosion of returns. While… read more...

Biotech Bonanza: 2019 Outlook On An Uphill Battle

via: SeekingAlpha at 2018-12-20 14:47:33:000

Biotech Pulse The stock market was on track for a solid double-digit return performance in 2018, until it entered the final quarter. The performance cart has been rattling ever since as the stock market's perception of risk has risen dramatically, leading to a sharp erosion of returns. While… read more...

Global Blood Therapeutics: Can The Rally Continue?

via: SeekingAlpha at 2018-12-08 02:44:25:000

"In chaos, there is fertility. " - Anais Nin Today, we revisit Global Blood Therapeutics ( GBT ) . This stock has had an up and down year as can be seen from the chart below. The shares have recently been on an upswing despite the current horrid sentiment in the market. The company jus… read more...

Global Blood Therapeutics: Can The Rally Continue?

via: SeekingAlpha at 2018-12-08 02:44:25:000

"In chaos, there is fertility. " - Anais Nin Today, we revisit Global Blood Therapeutics ( GBT ) . This stock has had an up and down year as can be seen from the chart below. The shares have recently been on an upswing despite the current horrid sentiment in the market. The company jus… read more...

Global Blood Therapeutics: Can The Rally Continue?

via: SeekingAlpha at 2018-12-08 02:44:25:000

"In chaos, there is fertility. " - Anais Nin Today, we revisit Global Blood Therapeutics ( GBT ) . This stock has had an up and down year as can be seen from the chart below. The shares have recently been on an upswing despite the current horrid sentiment in the market. The company jus… read more...

Global Blood Therapeutics: Can The Rally Continue?

via: SeekingAlpha at 2018-12-08 02:44:25:000

"In chaos, there is fertility. " - Anais Nin Today, we revisit Global Blood Therapeutics ( GBT ) . This stock has had an up and down year as can be seen from the chart below. The shares have recently been on an upswing despite the current horrid sentiment in the market. The company jus… read more...

JP and BIG among premarket losers

via: SeekingAlpha at 2018-12-07 09:11:34:000

Jupai Holdings (NYSE: JP ) -27% on Q3 earnings . More news on: Jupai Holdings, Viveve Medical, Inc., Big Lots, Inc., Stocks on the move, , Read more … read more...

Global Blood Therapeutics Delivers The Good News; What Is The Path Ahead?

via: SeekingAlpha at 2018-12-06 22:49:44:000

Preface Within my exclusive marketplace, The Formula , I look for assets that provide therapeutic differentiation (have superior efficacy and safety, serve unmet needs, have limited competition, etc.). I have one model portfolio of my top biotech stocks focused on conviction ideas with in… read more...

Global Blood Therapeutics Gets A Quick Advance Surprise By The FDA

via: SeekingAlpha at 2018-12-06 12:39:09:000

Recently, Global Blood Therapeutics ( GBT ) announced that the FDA agreed to give its sickle cell disease drug Voxelotor accelerated approval . Shares of the stock surged as high as 55% on the news to $49.14 per share. This is good news for the biotech which is looking to quickly get this t… read more...

Adobe Is Not For The Short Term - Cramer's Lightning Round (12/4/18)

via: SeekingAlpha at 2018-12-05 06:53:06:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, December 4 . Bullish Calls Booz Allen Hamilton Holding (BAH): Cramer thinks the stock is good but he prefers Accenture (ACN). Adobe (ADBE): The stock has run up a lot and it's not for the short… read more...

Global Blood's voxelotor shows positive action in late-stage sickle cell study; shares up 56%

via: SeekingAlpha at 2018-12-03 12:53:39:000

Global Blood Therapeutics ( GBT +55.7% ) is up on more than an 8x surge in volume on the heels of positive data from a Phase 3 clinical trial, HOPE , evaluating voxelotor in patients at least 12 years old with sickle cell disease (SCD). The results were presented at ASH in San Diego. … read more...

Global Blood's voxelotor shows positive action in late-stage sickle cell study; shares up 56%

via: SeekingAlpha at 2018-12-03 12:53:39:000

Global Blood Therapeutics ( GBT +55.7% ) is up on more than an 8x surge in volume on the heels of positive data from a Phase 3 clinical trial, HOPE , evaluating voxelotor in patients at least 12 years old with sickle cell disease (SCD). The results were presented at ASH in San Diego. … read more...

Healthcare and Industrial goods dominate midday movers

via: SeekingAlpha at 2018-12-03 12:46:15:000

More news on: Tesaro, Global Blood Therapeutics, Atossa Genetics, Inc., Stocks on the move, , Read more … read more...

Healthcare and Industrial goods dominate midday movers

via: SeekingAlpha at 2018-12-03 12:46:15:000

More news on: Tesaro, Global Blood Therapeutics, Atossa Genetics, Inc., Stocks on the move, , Read more … read more...

VIPS, BZUN among premarket gainers

via: SeekingAlpha at 2018-12-03 09:25:27:000

Tesaro (NASDAQ: TSRO ) +59% on acquisition by Glaxo for $75. More news on: Tesaro, Global Blood Therapeutics, Hudson Technologies, Inc., Stocks on the move, , Read more … read more...

VIPS, BZUN among premarket gainers

via: SeekingAlpha at 2018-12-03 09:25:27:000

Tesaro (NASDAQ: TSRO ) +59% on acquisition by Glaxo for $75. More news on: Tesaro, Global Blood Therapeutics, Hudson Technologies, Inc., Stocks on the move, , Read more … read more...

FDA accepts GBT's proposal for accelerated approval pathway for Voxelotor; shares up 42% premarket

via: SeekingAlpha at 2018-12-03 08:51:05:000

FDA agrees with Global Blood Therapeutics' (NASDAQ: GBT ) proposal relating to use of an accelerated approval pathway for voxelotor for the treatment of sickle cell disease (SCD). More news on: Global Blood Therapeutics, Healthcare stocks news, Read more … read more...

FDA accepts GBT's proposal for accelerated approval pathway for Voxelotor; shares up 42% premarket

via: SeekingAlpha at 2018-12-03 08:51:05:000

FDA agrees with Global Blood Therapeutics' (NASDAQ: GBT ) proposal relating to use of an accelerated approval pathway for voxelotor for the treatment of sickle cell disease (SCD). More news on: Global Blood Therapeutics, Healthcare stocks news, Read more … read more...

Global Blood FQ2 top line up 5%; earnings down 4%

via: SeekingAlpha at 2018-11-27 16:35:09:000

Global Blood Therapeutics (NASDAQ: GBT ) fiscal Q2 results (RMB million): Revenues: 247.1 (+5.3%). Growth due to increase in total subscriber base. More news on: Global Blood Therapeutics, Healthcare stocks news, Earnings news and commentary, Read more … read more...

Global Blood FQ2 top line up 5%; earnings down 4%

via: SeekingAlpha at 2018-11-27 16:35:09:000

Global Blood Therapeutics (NASDAQ: GBT ) fiscal Q2 results (RMB million): Revenues: 247.1 (+5.3%). Growth due to increase in total subscriber base. More news on: Global Blood Therapeutics, Healthcare stocks news, Earnings news and commentary, Read more … read more...

Global Blood FQ2 top line up 5%; earnings down 4%

via: SeekingAlpha at 2018-11-27 16:35:09:000

Global Blood Therapeutics (NASDAQ: GBT ) fiscal Q2 results (RMB million): Revenues: 247.1 (+5.3%). Growth due to increase in total subscriber base. More news on: Global Blood Therapeutics, Healthcare stocks news, Earnings news and commentary, Read more … read more...

Financial Exchange Stock Talk: Joe McCann On Global Blood Therapeutics

via: SeekingAlpha at 2018-11-20 13:48:58:000

Read more … read more...

Financial Exchange Stock Talk: Joe McCann On Global Blood Therapeutics

via: SeekingAlpha at 2018-11-20 13:48:58:000

Read more … read more...

Financial Exchange Stock Talk: Joe McCann On Global Blood Therapeutics

via: SeekingAlpha at 2018-11-20 13:48:58:000

Read more … read more...

Guerbet To Showcase Ongoing Collaboration with IBM Watson and Advanced Digital Solutions at RSNA 2018

via: PR Newswire at 2018-11-19 15:10:00:000

PRINCETON, N.J. , Nov. 19, 2018 /PRNewswire/ --Guerbet LLC USA (Guerbet), the U.S. affiliate of the global specialist in contrast agents and solutions for medical imaging, will feature its digital solutions including its ongoing collaboration with IBM Watson Health in medical imag… read more...

Biotechs getting slammed again, XBI down almost 4%

via: SeekingAlpha at 2018-11-12 11:45:16:000

In an all-too-frequent narrative, biotechs are getting roughed up yet again. The SPDR S&P Biotech ETF ( XBI -3.5% ) is in the red, albeit on below-average volume. The ETF has lost ~22% of its value in a little over two months. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, In… read more...

Biotechs getting slammed again, XBI down almost 4%

via: SeekingAlpha at 2018-11-12 11:45:16:000

In an all-too-frequent narrative, biotechs are getting roughed up yet again. The SPDR S&P Biotech ETF ( XBI -3.5% ) is in the red, albeit on below-average volume. The ETF has lost ~22% of its value in a little over two months. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, In… read more...

Biotechs getting slammed again, XBI down almost 4%

via: SeekingAlpha at 2018-11-12 11:45:16:000

In an all-too-frequent narrative, biotechs are getting roughed up yet again. The SPDR S&P Biotech ETF ( XBI -3.5% ) is in the red, albeit on below-average volume. The ETF has lost ~22% of its value in a little over two months. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, In… read more...

Global Blood Therapeutics beats by $0.03

via: SeekingAlpha at 2018-11-07 15:57:31:000

Global Blood Therapeutics (NASDAQ: GBT ): Q3 GAAP EPS of -$0.83 beats by $0.03. Cash and cash equivalents of $194.89M Press Release More news on: Global Blood Therapeutics, Earnings news and commentary, Healthcare stocks news, read more...

Global Blood Therapeutics beats by $0.03

via: SeekingAlpha at 2018-11-07 15:57:31:000

Global Blood Therapeutics (NASDAQ: GBT ): Q3 GAAP EPS of -$0.83 beats by $0.03. Cash and cash equivalents of $194.89M Press Release More news on: Global Blood Therapeutics, Earnings news and commentary, Healthcare stocks news, read more...

Global Blood Therapeutics beats by $0.03

via: SeekingAlpha at 2018-11-07 15:57:31:000

Global Blood Therapeutics (NASDAQ: GBT ): Q3 GAAP EPS of -$0.83 beats by $0.03. Cash and cash equivalents of $194.89M Press Release More news on: Global Blood Therapeutics, Earnings news and commentary, Healthcare stocks news, read more...

Global Blood Therapeutics: FDA/ASH Workshop Bodes Well For Accelerated Approval Prospects

via: SeekingAlpha at 2018-11-05 02:00:29:000

Preface Within my exclusive marketplace, The Formula , I look for assets that provide therapeutic differentiation (have superior efficacy and safety, serve unmet needs, have limited competition, etc.). I have one model portfolio of my top biotech stocks focused on conviction ideas with in… read more...

Global Blood Therapeutics: FDA/ASH Workshop Bodes Well For Accelerated Approval Prospects

via: SeekingAlpha at 2018-11-05 02:00:29:000

Preface Within my exclusive marketplace, The Formula , I look for assets that provide therapeutic differentiation (have superior efficacy and safety, serve unmet needs, have limited competition, etc.). I have one model portfolio of my top biotech stocks focused on conviction ideas with in… read more...

Lifshitz & Miller LLP Announces Investigation of Access National Corporation, Engility Holdings, Inc., Floor & Decor Holdings, Inc., Global Blood Therapeutics, Inc., Intrexon Corporation, Keryx Biopharmaceuticals, Inc., Nevada Gold & Casinos, Inc., and Sonic Corp.

via: PR Newswire at 2018-11-01 15:37:00:000

NEW YORK , Nov. 1, 2018 /PRNewswire/ -- Access National Corporation (ANCX) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the sale of ANCX to Union Bankshares Corporation for 0.75 shares of Union common stock per… read more...

Lifshitz & Miller LLP Announces Investigation of Access National Corporation, Engility Holdings, Inc., Floor & Decor Holdings, Inc., Global Blood Therapeutics, Inc., Intrexon Corporation, Keryx Biopharmaceuticals, Inc., Nevada Gold & Casinos, Inc., and Sonic Corp.

via: PR Newswire at 2018-11-01 15:37:00:000

NEW YORK , Nov. 1, 2018 /PRNewswire/ -- Access National Corporation (ANCX) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the sale of ANCX to Union Bankshares Corporation for 0.75 shares of Union common stock per… read more...

Lifshitz & Miller LLP Announces Investigation of Access National Corporation, Engility Holdings, Inc., Floor & Decor Holdings, Inc., Global Blood Therapeutics, Inc., Intrexon Corporation, Keryx Biopharmaceuticals, Inc., Nevada Gold & Casinos, Inc., and Sonic Corp.

via: PR Newswire at 2018-11-01 15:37:00:000

NEW YORK , Nov. 1, 2018 /PRNewswire/ -- Access National Corporation (ANCX) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the sale of ANCX to Union Bankshares Corporation for 0.75 shares of Union common stock per… read more...

Global Blood up 9% as FDA-ASH workshop on sickle cell disease continues

via: SeekingAlpha at 2018-10-18 10:09:04:000

Investors are behaving like the FDA-ASH Sickle Cell Disease Clinical Endpoints Workshop , in its second day in Washington, DC, is bullish for Global Blood Therapeutics ( GBT +9.2% ). Shares have rallied 25% over the past five trading days. More news on: Global Blood Therapeu… read more...

Global Blood up 9% as FDA-ASH workshop on sickle cell disease continues

via: SeekingAlpha at 2018-10-18 10:09:04:000

Investors are behaving like the FDA-ASH Sickle Cell Disease Clinical Endpoints Workshop , in its second day in Washington, DC, is bullish for Global Blood Therapeutics ( GBT +9.2% ). Shares have rallied 25% over the past five trading days. More news on: Global Blood Therapeu… read more...

Global Blood up 9% as FDA-ASH workshop on sickle cell disease continues

via: SeekingAlpha at 2018-10-18 10:09:04:000

Investors are behaving like the FDA-ASH Sickle Cell Disease Clinical Endpoints Workshop , in its second day in Washington, DC, is bullish for Global Blood Therapeutics ( GBT +9.2% ). Shares have rallied 25% over the past five trading days. More news on: Global Blood Therapeu… read more...

Global Blood up 9% as FDA-ASH workshop on sickle cell disease continues

via: SeekingAlpha at 2018-10-18 10:09:04:000

Investors are behaving like the FDA-ASH Sickle Cell Disease Clinical Endpoints Workshop , in its second day in Washington, DC, is bullish for Global Blood Therapeutics ( GBT +9.2% ). Shares have rallied 25% over the past five trading days. More news on: Global Blood Therapeu… read more...

Global Blood up 9% as FDA-ASH workshop on sickle cell disease continues

via: SeekingAlpha at 2018-10-18 10:09:04:000

Investors are behaving like the FDA-ASH Sickle Cell Disease Clinical Endpoints Workshop , in its second day in Washington, DC, is bullish for Global Blood Therapeutics ( GBT +9.2% ). Shares have rallied 25% over the past five trading days. More news on: Global Blood Therapeu… read more...

Novartis' crizanlizumab showed effect on vaso-occlusive crises in mid-stage sickle cell study

via: SeekingAlpha at 2018-10-10 07:21:41:000

A post hoc analysis of a Phase 2 clinical trial, SUSTAIN, evaluating Novartis' (NYSE: NVS ) crizanlizumab in patients with sickle cell disease (SCD) showed that more patients treated with the antibody (35.8%) did not experience a vaso-occlusive crisis (VOC) than those receiving a placebo (… read more...

Novartis' crizanlizumab showed effect on vaso-occlusive crises in mid-stage sickle cell study

via: SeekingAlpha at 2018-10-10 07:21:41:000

A post hoc analysis of a Phase 2 clinical trial, SUSTAIN, evaluating Novartis' (NYSE: NVS ) crizanlizumab in patients with sickle cell disease (SCD) showed that more patients treated with the antibody (35.8%) did not experience a vaso-occlusive crisis (VOC) than those receiving a placebo (… read more...

Novartis' crizanlizumab showed effect on vaso-occlusive crises in mid-stage sickle cell study

via: SeekingAlpha at 2018-10-10 07:21:41:000

A post hoc analysis of a Phase 2 clinical trial, SUSTAIN, evaluating Novartis' (NYSE: NVS ) crizanlizumab in patients with sickle cell disease (SCD) showed that more patients treated with the antibody (35.8%) did not experience a vaso-occlusive crisis (VOC) than those receiving a placebo (… read more...

Novartis' crizanlizumab showed effect on vaso-occlusive crises in mid-stage sickle cell study

via: SeekingAlpha at 2018-10-10 07:21:41:000

A post hoc analysis of a Phase 2 clinical trial, SUSTAIN, evaluating Novartis' (NYSE: NVS ) crizanlizumab in patients with sickle cell disease (SCD) showed that more patients treated with the antibody (35.8%) did not experience a vaso-occlusive crisis (VOC) than those receiving a placebo (… read more...

Global Blood Therapeutics: Making Sense Of Statistics And The Sacred VOC Endpoint

via: SeekingAlpha at 2018-09-27 08:14:51:000

Preface Global Blood Therapeutics ( GBT ) released HOPE part A data in June that was met with mixed feelings. Part of the mixed feelings was associated with a lack of insight into a key secondary endpoint: vaso-occlusive crises [VOC]. I have argued before that "numerical reductions" in VOC… read more...

Global Blood Therapeutics: Making Sense Of Statistics And The Sacred VOC Endpoint

via: SeekingAlpha at 2018-09-27 08:14:51:000

Preface Global Blood Therapeutics ( GBT ) released HOPE part A data in June that was met with mixed feelings. Part of the mixed feelings was associated with a lack of insight into a key secondary endpoint: vaso-occlusive crises [VOC]. I have argued before that "numerical reductions" in VOC… read more...

Global Blood Therapeutics: Making Sense Of Statistics And The Sacred VOC Endpoint

via: SeekingAlpha at 2018-09-27 08:14:51:000

Preface Global Blood Therapeutics ( GBT ) released HOPE part A data in June that was met with mixed feelings. Part of the mixed feelings was associated with a lack of insight into a key secondary endpoint: vaso-occlusive crises [VOC]. I have argued before that "numerical reductions" in VOC… read more...

Investing In The 'Softer Side' Of Biotech, Without Getting Emotional

via: SeekingAlpha at 2018-09-18 07:30:00:000

Biotech has hit a rough spot of late. Some of the most popular biotech exchange-traded funds are seeing record outflows as investors flee on disappointing merger & acquisition activity in the sector. The $9.3 billion SPDR S&P Biotech ETF (XBI) saw investors cash out $365 million last… read more...

Investing In The 'Softer Side' Of Biotech, Without Getting Emotional

via: SeekingAlpha at 2018-09-18 07:30:00:000

Biotech has hit a rough spot of late. Some of the most popular biotech exchange-traded funds are seeing record outflows as investors flee on disappointing merger & acquisition activity in the sector. The $9.3 billion SPDR S&P Biotech ETF (XBI) saw investors cash out $365 million last… read more...

Investing In The 'Softer Side' Of Biotech, Without Getting Emotional

via: SeekingAlpha at 2018-09-18 07:30:00:000

Biotech has hit a rough spot of late. Some of the most popular biotech exchange-traded funds are seeing record outflows as investors flee on disappointing merger & acquisition activity in the sector. The $9.3 billion SPDR S&P Biotech ETF (XBI) saw investors cash out $365 million last… read more...

Global Blood Therapeutics: STAT Article Sparks Worry, But Much Of It Is Unwarranted

via: SeekingAlpha at 2018-09-17 20:21:42:000

A STAT article released last Thursday was met with immediate selling in Global Blood Therapeutics (GBT), as shares took a considerable dip on above-average volume: Chart courtesy of StockCharts.com The article's debut happened to coincide with The Sickle Cell Therapeutics Conference,… read more...

Global Blood Therapeutics: STAT Article Sparks Worry, But Much Of It Is Unwarranted

via: SeekingAlpha at 2018-09-17 20:21:42:000

A STAT article released last Thursday was met with immediate selling in Global Blood Therapeutics (GBT), as shares took a considerable dip on above-average volume: Chart courtesy of StockCharts.com The article's debut happened to coincide with The Sickle Cell Therapeutics Conference,… read more...

Global Blood Therapeutics: STAT Article Sparks Worry, But Much Of It Is Unwarranted

via: SeekingAlpha at 2018-09-17 20:21:42:000

A STAT article released last Thursday was met with immediate selling in Global Blood Therapeutics (GBT), as shares took a considerable dip on above-average volume: Chart courtesy of StockCharts.com The article's debut happened to coincide with The Sickle Cell Therapeutics Conference,… read more...

INVESTIGATION ALERT: The Schall Law Firm Announces It is Investigating Claims against Global Blood Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-09-14 18:07:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Global Blood Therapeutics, Inc. (Global Blood or the Company) (NASDAQ: GBT ) for violations of 10(b) and 20(a… read more...

INVESTIGATION ALERT: The Schall Law Firm Announces It is Investigating Claims against Global Blood Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-09-14 18:07:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Global Blood Therapeutics, Inc. (Global Blood or the Company) (NASDAQ: GBT ) for violations of 10(b) and 20(a… read more...

INVESTIGATION ALERT: The Schall Law Firm Announces It is Investigating Claims against Global Blood Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-09-14 18:07:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Global Blood Therapeutics, Inc. (Global Blood or the Company) (NASDAQ: GBT ) for violations of 10(b) and 20(a… read more...

INVESTIGATION ALERT: The Schall Law Firm Announces It is Investigating Claims against Global Blood Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-09-14 18:07:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Global Blood Therapeutics, Inc. (Global Blood or the Company) (NASDAQ: GBT ) for violations of 10(b) and 20(a… read more...

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Global Blood Therapeutics, Inc. - GBT

via: Business Wire at 2018-09-13 18:16:00:000

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Global Blood Therapeutics, Inc. (NASDAQ: GBT) resulting from allegations that Global Blood may have issued materially misleading business information to t… read more...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Global Blood Therapeutics, Inc. - GBT

via: PR Newswire at 2018-09-13 16:05:00:000

NEW YORK , Sept. 13, 2018 /PRNewswire/ --Pomerantz LLP is investigating claims on behalf of investors of Global Blood Therapeutics, Inc. ("Global Blood" or the "Company") (NASDAQ: GBT). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com o… read more...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Global Blood Therapeutics, Inc. (GBT)

via: PR Newswire at 2018-09-13 12:33:00:000

NEW YORK , Sept. 13, 2018 /PRNewswire/ --Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Global Blood Therapeutics, Inc. ("Global Blood" or the "Company") (NASDAQ: GBT). Such investors are encouraged to obta… read more...

Global Blood down 5% premarket on bearish Feuerstein report

via: SeekingAlpha at 2018-09-13 08:56:28:000

Global Blood Therapeutics (NASDAQ: GBT ) slips 5% premarket on light volume on the heels of a bearish report by STAT News' Adam Feuerstein who cites the risk in securing accelerated FDA approval for sickle cell med voxelotor. More news on: Global Blood Therapeutics, Healthcar… read more...

Global Blood Therapeutics: Iclacumab To Deliver The Pipeline Synergy With Voxelotor

via: SeekingAlpha at 2018-09-10 09:44:09:000

Such a study indicates that the greatest investment reward comes to those who by good luck or good sense find the occasional company that over the years can grow in sales and profits far more than industry as a whole. - The Father of Growth Investing (Phillip Fisher) Global Blood Therapeu… read more...

Global Blood Therapeutics: Iclacumab To Deliver The Pipeline Synergy With Voxelotor

via: SeekingAlpha at 2018-09-10 09:44:09:000

Such a study indicates that the greatest investment reward comes to those who by good luck or good sense find the occasional company that over the years can grow in sales and profits far more than industry as a whole. - The Father of Growth Investing (Phillip Fisher) Global Blood Therapeu… read more...

Global Blood Therapeutics: Iclacumab To Deliver The Pipeline Synergy With Voxelotor

via: SeekingAlpha at 2018-09-10 09:44:09:000

Such a study indicates that the greatest investment reward comes to those who by good luck or good sense find the occasional company that over the years can grow in sales and profits far more than industry as a whole. - The Father of Growth Investing (Phillip Fisher) Global Blood Therapeu… read more...

Welcome To The Formula - A Biotechnology Marketplace

via: SeekingAlpha at 2018-09-04 10:00:00:000

(Editors' Note: This article is meant as an introduction for The Formula , a new Marketplace service by Clover Biotech Research.) The Formula Welcome To Seeking Alpha's Next Big Community! Your subscription and confidence in our service are important to me. While I cannot promise por… read more...

Welcome To The Formula - A Biotechnology Marketplace

via: SeekingAlpha at 2018-09-04 10:00:00:000

(Editors' Note: This article is meant as an introduction for The Formula , a new Marketplace service by Clover Biotech Research.) The Formula Welcome To Seeking Alpha's Next Big Community! Your subscription and confidence in our service are important to me. While I cannot promise por… read more...

Welcome To The Formula - A Biotechnology Marketplace

via: SeekingAlpha at 2018-09-04 10:00:00:000

(Editors' Note: This article is meant as an introduction for The Formula , a new Marketplace service by Clover Biotech Research.) The Formula Welcome To Seeking Alpha's Next Big Community! Your subscription and confidence in our service are important to me. While I cannot promise por… read more...

Global Blood Therapeutics And Inclacumab: Some Context

via: SeekingAlpha at 2018-08-30 12:56:18:000

Global Blood Therapeutics ( GBT ) recently announced that it has entered into an exclusive worldwide licensing agreement with Roche ( OTCQX:RHHBY ) for the development and commercialization of inclacumab, a monoclonal antibody against P-selectin. In a short piece, I try to provide some per… read more...

Global Blood Therapeutics And Inclacumab: Some Context

via: SeekingAlpha at 2018-08-30 12:56:18:000

Global Blood Therapeutics ( GBT ) recently announced that it has entered into an exclusive worldwide licensing agreement with Roche ( OTCQX:RHHBY ) for the development and commercialization of inclacumab, a monoclonal antibody against P-selectin. In a short piece, I try to provide some per… read more...

Global Blood Therapeutics And Inclacumab: Some Context

via: SeekingAlpha at 2018-08-30 12:56:18:000

Global Blood Therapeutics ( GBT ) recently announced that it has entered into an exclusive worldwide licensing agreement with Roche ( OTCQX:RHHBY ) for the development and commercialization of inclacumab, a monoclonal antibody against P-selectin. In a short piece, I try to provide some per… read more...

Biotech Analysis Central Pharma News: Novartis' Positive News, Roche Unloads Drug, Zai Lab Suffers Failure

via: SeekingAlpha at 2018-08-27 23:57:00:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Novartis Ends Up With Positive Trend In Late-Stage Breast Cancer Study News: Recently, Novartis (NVS) announced that it had met the primary endpoin… read more...

Biotech Analysis Central Pharma News: Novartis' Positive News, Roche Unloads Drug, Zai Lab Suffers Failure

via: SeekingAlpha at 2018-08-27 23:57:00:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Novartis Ends Up With Positive Trend In Late-Stage Breast Cancer Study News: Recently, Novartis (NVS) announced that it had met the primary endpoin… read more...

Money flow stays positive in biotechs, XBI up 6% since last week

via: SeekingAlpha at 2018-08-27 11:39:49:000

Biotechs continue their modest rally. The SPDR S&P Biotech ETF ( XBI +1.9% ) is up albeit on below average. It has jumped 6% since last week. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the … read more...

Evaluation Of Crispr Therapeutics

via: SeekingAlpha at 2018-08-27 09:30:00:000

Gene-editing based therapy is one of the hottest areas within biotech section. Investors have great interest in this field, and are hopeful that it could dramatically change the future therapeutics landscape and cure many diseases instead of just alleviating symptoms. Gene editing technology r… read more...

Global Blood in-licenses sickle cell candidate from Roche; shares up 2% premarket

via: SeekingAlpha at 2018-08-23 08:48:11:000

Global Blood Therapeutics (NASDAQ: GBT ) is up 2% premarket on light volume on the heels of its global licensing deal with Roche ( OTCQX:RHHBY ) for the development and commercialization of inclacumab, a P-selectin-targeting monoclonal antibody, for the treatment of vaso-occlus… read more...

Global Blood in-licenses sickle cell candidate from Roche; shares up 2% premarket

via: SeekingAlpha at 2018-08-23 08:48:11:000

Global Blood Therapeutics (NASDAQ: GBT ) is up 2% premarket on light volume on the heels of its global licensing deal with Roche ( OTCQX:RHHBY ) for the development and commercialization of inclacumab, a P-selectin-targeting monoclonal antibody, for the treatment of vaso-occlus… read more...

Global Blood in-licenses sickle cell candidate from Roche; shares up 2% premarket

via: SeekingAlpha at 2018-08-23 08:48:11:000

Global Blood Therapeutics (NASDAQ: GBT ) is up 2% premarket on light volume on the heels of its global licensing deal with Roche ( OTCQX:RHHBY ) for the development and commercialization of inclacumab, a P-selectin-targeting monoclonal antibody, for the treatment of vaso-occlus… read more...

Investors shun healthcare stocks in broad market selloff

via: SeekingAlpha at 2018-08-15 10:14:45:000

Healthcare stocks are taking it on the chin in today's broad selloff, some more than others. The SPDR S&P Biotech ETF ( XBI -2% ), for example, is down more than the major indexes. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Global Blood Therapeutics, Healthcare stoc… read more...

Investors shun healthcare stocks in broad market selloff

via: SeekingAlpha at 2018-08-15 10:14:45:000

Healthcare stocks are taking it on the chin in today's broad selloff, some more than others. The SPDR S&P Biotech ETF ( XBI -2% ), for example, is down more than the major indexes. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Global Blood Therapeutics, Healthcare stoc… read more...

Investors shun healthcare stocks in broad market selloff

via: SeekingAlpha at 2018-08-15 10:14:45:000

Healthcare stocks are taking it on the chin in today's broad selloff, some more than others. The SPDR S&P Biotech ETF ( XBI -2% ), for example, is down more than the major indexes. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Global Blood Therapeutics, Healthcare stoc… read more...

Investors shun healthcare stocks in broad market selloff

via: SeekingAlpha at 2018-08-15 10:14:45:000

Healthcare stocks are taking it on the chin in today's broad selloff, some more than others. The SPDR S&P Biotech ETF ( XBI -2% ), for example, is down more than the major indexes. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Global Blood Therapeutics, Healthcare stoc… read more...

Guerbet Announces Commercial Partnership With Imalogix(TM) to Deliver Diagnostic and Interventional Imaging Care Optimization

via: PR Newswire at 2018-08-13 15:50:00:000

PRINCETON, N.J. , Aug. 13, 2018 /PRNewswire/ -- Guerbet LLC USA , the U.S. affiliate of the global specialist in contrast product and solutions for medical imaging, announced today a commercial partnership with Imalogix, a leader in artificial intelligence process and workflow so… read more...

Guerbet Announces Commercial Partnership With Imalogix(TM) to Deliver Diagnostic and Interventional Imaging Care Optimization

via: PR Newswire at 2018-08-13 15:50:00:000

PRINCETON, N.J. , Aug. 13, 2018 /PRNewswire/ -- Guerbet LLC USA , the U.S. affiliate of the global specialist in contrast product and solutions for medical imaging, announced today a commercial partnership with Imalogix, a leader in artificial intelligence process and workflow so… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-06 07:57:30:000

Alder Biopharmaceuticals (NASDAQ: ALDR ) initiated with Overweight rating and $28 (47% upside) price target at Piper Jaffray. More news on: Alder Biopharmaceuticals Inc., Global Blood Therapeutics, Sage Therapeutics, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-06 07:57:30:000

Alder Biopharmaceuticals (NASDAQ: ALDR ) initiated with Overweight rating and $28 (47% upside) price target at Piper Jaffray. More news on: Alder Biopharmaceuticals Inc., Global Blood Therapeutics, Sage Therapeutics, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-06 07:57:30:000

Alder Biopharmaceuticals (NASDAQ: ALDR ) initiated with Overweight rating and $28 (47% upside) price target at Piper Jaffray. More news on: Alder Biopharmaceuticals Inc., Global Blood Therapeutics, Sage Therapeutics, Healthcare stocks news, Stocks on the move, , Read more … read more...

Global Blood up 6% after Q2 report

via: SeekingAlpha at 2018-08-03 11:36:48:000

Global Blood Therapeutics ( GBT +6.3% ) is up on average volume after posting Q2 results yesterday after the close. Highlights: More news on: Global Blood Therapeutics, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

Global Blood up 6% after Q2 report

via: SeekingAlpha at 2018-08-03 11:36:48:000

Global Blood Therapeutics ( GBT +6.3% ) is up on average volume after posting Q2 results yesterday after the close. Highlights: More news on: Global Blood Therapeutics, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

Global Blood up 6% after Q2 report

via: SeekingAlpha at 2018-08-03 11:36:48:000

Global Blood Therapeutics ( GBT +6.3% ) is up on average volume after posting Q2 results yesterday after the close. Highlights: More news on: Global Blood Therapeutics, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

Global Blood Therapeutics beats by $0.10

via: SeekingAlpha at 2018-08-02 16:59:49:000

Global Blood Therapeutics (NASDAQ: GBT ): Q2 EPS of -$0.78 beats by $0.10 . More news on: Global Blood Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Sickle Cell Disease Breakthrough: Global Blood Therapeutics' Antisickling Agent Voxelotor

via: SeekingAlpha at 2018-07-31 08:35:18:000

Currently in talks with the FDA to accelerate their candidate's route to market (which could be as early as 2019), Global Blood Therapeutics (GBT) is banking on their Phase 3 part A results and a trophy cabinet of accolades (breakthrough drug designation, orphan drug designation) to disru… read more...

Sickle Cell Disease Breakthrough: Global Blood Therapeutics' Antisickling Agent Voxelotor

via: SeekingAlpha at 2018-07-31 08:35:18:000

Currently in talks with the FDA to accelerate their candidate's route to market (which could be as early as 2019), Global Blood Therapeutics (GBT) is banking on their Phase 3 part A results and a trophy cabinet of accolades (breakthrough drug designation, orphan drug designation) to disru… read more...

Global Blood Therapeutics: What The Market Is Missing

via: SeekingAlpha at 2018-07-26 11:22:31:000

Introduction There have been quite a few articles written about Global Blood Therapeutics ( GBT ) on Seeking Alpha (I written have two of them; here and here ). Rather than reiterate what most will find elsewhere, this time I'm going to take a different approach by breaking down poss… read more...

Global Blood Therapeutics: What The Market Is Missing

via: SeekingAlpha at 2018-07-26 11:22:31:000

Introduction There have been quite a few articles written about Global Blood Therapeutics ( GBT ) on Seeking Alpha (I written have two of them; here and here ). Rather than reiterate what most will find elsewhere, this time I'm going to take a different approach by breaking down poss… read more...

Global Blood Therapeutics: What The Market Is Missing

via: SeekingAlpha at 2018-07-26 11:22:31:000

Introduction There have been quite a few articles written about Global Blood Therapeutics ( GBT ) on Seeking Alpha (I written have two of them; here and here ). Rather than reiterate what most will find elsewhere, this time I'm going to take a different approach by breaking down poss… read more...

Guerbet Announces AHRA Charitable Contribution to Support Next Generation Leaders in Medical Imaging

via: PR Newswire at 2018-07-24 13:22:00:000

PRINCETON, N.J. , July 24, 2018 /PRNewswire/ -- Guerbet LLC USA , the U.S. affiliate of the global specialist in contrast product and solutions for medical imaging, announced today a contribution of $50,000 to the Association for Medical Imaging Management (AHRA) "Defining Our F… read more...

Guerbet Announces AHRA Charitable Contribution to Support Next Generation Leaders in Medical Imaging

via: PR Newswire at 2018-07-24 13:22:00:000

PRINCETON, N.J. , July 24, 2018 /PRNewswire/ -- Guerbet LLC USA , the U.S. affiliate of the global specialist in contrast product and solutions for medical imaging, announced today a contribution of $50,000 to the Association for Medical Imaging Management (AHRA) "Defining Our F… read more...

3 Solid Mid-Cap Biotechs To Close Out 2018

via: SeekingAlpha at 2018-07-22 08:38:55:000

Ah, Winter will be here before we know it. Below are three mid-cap biotechnology stocks I believe have great risk/reward ratios and significant remaining upside before the dead of Winter hits (January). All of the mid-cap picks I present: have high cash/low debt are technical momentu… read more...

3 Solid Mid-Cap Biotechs To Close Out 2018

via: SeekingAlpha at 2018-07-22 08:38:55:000

Ah, Winter will be here before we know it. Below are three mid-cap biotechnology stocks I believe have great risk/reward ratios and significant remaining upside before the dead of Winter hits (January). All of the mid-cap picks I present: have high cash/low debt are technical momentu… read more...

Global Blood: Countering Short Myths And Market Uncertainty Surrounding HOPE Part A Data

via: SeekingAlpha at 2018-07-13 01:03:18:000

Recently, shorts have piled on Global Blood Therapeutics ( GBT ) in light of investor uncertainty. In the following article, I will address some of the claims I have seen on the internet. We will also discuss what investors have to look forward to. Common Short Concerns (Myths) 1. Global… read more...

Global Blood: Countering Short Myths And Market Uncertainty Surrounding HOPE Part A Data

via: SeekingAlpha at 2018-07-13 01:03:18:000

Recently, shorts have piled on Global Blood Therapeutics ( GBT ) in light of investor uncertainty. In the following article, I will address some of the claims I have seen on the internet. We will also discuss what investors have to look forward to. Common Short Concerns (Myths) 1. Global… read more...

Global Blood: Countering Short Myths And Market Uncertainty Surrounding HOPE Part A Data

via: SeekingAlpha at 2018-07-13 01:03:18:000

Recently, shorts have piled on Global Blood Therapeutics ( GBT ) in light of investor uncertainty. In the following article, I will address some of the claims I have seen on the internet. We will also discuss what investors have to look forward to. Common Short Concerns (Myths) 1. Global… read more...

Global Blood: Countering Short Myths And Market Uncertainty Surrounding HOPE Part A Data

via: SeekingAlpha at 2018-07-13 01:03:18:000

Recently, shorts have piled on Global Blood Therapeutics ( GBT ) in light of investor uncertainty. In the following article, I will address some of the claims I have seen on the internet. We will also discuss what investors have to look forward to. Common Short Concerns (Myths) 1. Global… read more...

Global Blood: Countering Short Myths And Market Uncertainty Surrounding HOPE Part A Data

via: SeekingAlpha at 2018-07-13 01:03:18:000

Recently, shorts have piled on Global Blood Therapeutics ( GBT ) in light of investor uncertainty. In the following article, I will address some of the claims I have seen on the internet. We will also discuss what investors have to look forward to. Common Short Concerns (Myths) 1. Global… read more...

Global Blood: Countering Short Myths And Market Uncertainty Surrounding HOPE Part A Data

via: SeekingAlpha at 2018-07-13 01:03:18:000

Recently, shorts have piled on Global Blood Therapeutics ( GBT ) in light of investor uncertainty. In the following article, I will address some of the claims I have seen on the internet. We will also discuss what investors have to look forward to. Common Short Concerns (Myths) 1. Global… read more...

Global Blood: Countering Short Myths And Market Uncertainty Surrounding HOPE Part A Data

via: SeekingAlpha at 2018-07-13 01:03:18:000

Recently, shorts have piled on Global Blood Therapeutics ( GBT ) in light of investor uncertainty. In the following article, I will address some of the claims I have seen on the internet. We will also discuss what investors have to look forward to. Common Short Concerns (Myths) 1. Global… read more...

Global Blood Seeks Accelerated Approval In Light Of HOPE Data

via: SeekingAlpha at 2018-06-29 14:48:56:000

Figure 1: Global Blood, again, steps on the regulatory accelerator for their sickle cell candidate, Voxelotor Global Blood Therapeutics ( GBT ) remains on track in catapulting Voxelotor into a large orphan market hungry for new therapeutics. Below, we will assess the latest data and post… read more...

Global Blood Seeks Accelerated Approval In Light Of HOPE Data

via: SeekingAlpha at 2018-06-29 14:48:56:000

Figure 1: Global Blood, again, steps on the regulatory accelerator for their sickle cell candidate, Voxelotor Global Blood Therapeutics ( GBT ) remains on track in catapulting Voxelotor into a large orphan market hungry for new therapeutics. Below, we will assess the latest data and post… read more...

Global Blood Seeks Accelerated Approval In Light Of HOPE Data

via: SeekingAlpha at 2018-06-29 14:48:56:000

Figure 1: Global Blood, again, steps on the regulatory accelerator for their sickle cell candidate, Voxelotor Global Blood Therapeutics ( GBT ) remains on track in catapulting Voxelotor into a large orphan market hungry for new therapeutics. Below, we will assess the latest data and post… read more...

Global Blood Seeks Accelerated Approval In Light Of HOPE Data

via: SeekingAlpha at 2018-06-29 14:48:56:000

Figure 1: Global Blood, again, steps on the regulatory accelerator for their sickle cell candidate, Voxelotor Global Blood Therapeutics ( GBT ) remains on track in catapulting Voxelotor into a large orphan market hungry for new therapeutics. Below, we will assess the latest data and post… read more...

Global Blood Seeks Accelerated Approval In Light Of HOPE Data

via: SeekingAlpha at 2018-06-29 14:48:56:000

Figure 1: Global Blood, again, steps on the regulatory accelerator for their sickle cell candidate, Voxelotor Global Blood Therapeutics ( GBT ) remains on track in catapulting Voxelotor into a large orphan market hungry for new therapeutics. Below, we will assess the latest data and post… read more...

Rounds Report: Global Blood Therapeutics Made A Strong Run Due To The Positive Clinical Binary

via: SeekingAlpha at 2018-06-29 03:19:15:000

Understanding both the power of compound interest and the difficulty of getting it is the heart and soul of understanding a lot of things. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for June 27, 2018. As usual, well elucidate … read more...

Rounds Report: Global Blood Therapeutics Made A Strong Run Due To The Positive Clinical Binary

via: SeekingAlpha at 2018-06-29 03:19:15:000

Understanding both the power of compound interest and the difficulty of getting it is the heart and soul of understanding a lot of things. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for June 27, 2018. As usual, well elucidate … read more...

Rounds Report: Global Blood Therapeutics Made A Strong Run Due To The Positive Clinical Binary

via: SeekingAlpha at 2018-06-29 03:19:15:000

Understanding both the power of compound interest and the difficulty of getting it is the heart and soul of understanding a lot of things. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for June 27, 2018. As usual, well elucidate … read more...

Rounds Report: Global Blood Therapeutics Made A Strong Run Due To The Positive Clinical Binary

via: SeekingAlpha at 2018-06-29 03:19:15:000

Understanding both the power of compound interest and the difficulty of getting it is the heart and soul of understanding a lot of things. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for June 27, 2018. As usual, well elucidate … read more...

Rounds Report: Global Blood Therapeutics Made A Strong Run Due To The Positive Clinical Binary

via: SeekingAlpha at 2018-06-29 03:19:15:000

Understanding both the power of compound interest and the difficulty of getting it is the heart and soul of understanding a lot of things. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for June 27, 2018. As usual, well elucidate … read more...

Global Blood Therapeutics target hiked to Street-high $96 at Cantor Fitzgerald

via: SeekingAlpha at 2018-06-27 10:15:27:000

Global Blood Therapeutics ( GBT -4.4% ) is lower as investors apparently overlook positive results for a late-stage trial of its sickle cell disease therapy and instead focus on the company's decision not to enroll any more patients for testing until it finishes discussions with the FDA…. read more...

Global Blood Therapeutics target hiked to Street-high $96 at Cantor Fitzgerald

via: SeekingAlpha at 2018-06-27 10:15:27:000

Global Blood Therapeutics ( GBT -4.4% ) is lower as investors apparently overlook positive results for a late-stage trial of its sickle cell disease therapy and instead focus on the company's decision not to enroll any more patients for testing until it finishes discussions with the FDA…. read more...

Premarket Losers as of 9:05 am (6/27/2018)

via: SeekingAlpha at 2018-06-27 09:28:23:000

AQXP -83% after trial failure . More news on: Aquinox Pharmaceuticals, Inc., Summit Therapeutics, Pain Therapeutics, Stocks on the move, Read more … read more...

Premarket Losers as of 9:05 am (6/27/2018)

via: SeekingAlpha at 2018-06-27 09:28:23:000

AQXP -83% after trial failure . More news on: Aquinox Pharmaceuticals, Inc., Summit Therapeutics, Pain Therapeutics, Stocks on the move, Read more … read more...

Global Blood -7% despite positive data from sickle cell drug trial

via: SeekingAlpha at 2018-06-27 08:13:49:000

Global Blood Therapeutics (NASDAQ: GBT ) -6.9% premarket despite announcing positive results and achieving its primary endpoint in a Phase 3 clinical trial of its voxelotor treatment for sickle cell disease. More news on: Global Blood Therapeutics, Healthcare stocks news, Read more… read more...

Global Blood -7% despite positive data from sickle cell drug trial

via: SeekingAlpha at 2018-06-27 08:13:49:000

Global Blood Therapeutics (NASDAQ: GBT ) -6.9% premarket despite announcing positive results and achieving its primary endpoint in a Phase 3 clinical trial of its voxelotor treatment for sickle cell disease. More news on: Global Blood Therapeutics, Healthcare stocks news, Read more… read more...

Global Blood Therapeutics: What The Recent HOPE-KIDS 1 Data Foretells

via: SeekingAlpha at 2018-06-22 08:13:08:000

The market is not a weighing machine, on which the value of each issue is recorded by an exact and impersonal mechanism, in accordance with its specific qualities. Rather should we say that the market is a voting machine, whereon countless individuals register choices which are the product pa… read more...

Global Blood Therapeutics: What The Recent HOPE-KIDS 1 Data Foretells

via: SeekingAlpha at 2018-06-22 08:13:08:000

The market is not a weighing machine, on which the value of each issue is recorded by an exact and impersonal mechanism, in accordance with its specific qualities. Rather should we say that the market is a voting machine, whereon countless individuals register choices which are the product pa… read more...

Global Blood Therapeutics: What The Recent HOPE-KIDS 1 Data Foretells

via: SeekingAlpha at 2018-06-22 08:13:08:000

The market is not a weighing machine, on which the value of each issue is recorded by an exact and impersonal mechanism, in accordance with its specific qualities. Rather should we say that the market is a voting machine, whereon countless individuals register choices which are the product pa… read more...

Global Blood Therapeutics: What The Recent HOPE-KIDS 1 Data Foretells

via: SeekingAlpha at 2018-06-22 08:13:08:000

The market is not a weighing machine, on which the value of each issue is recorded by an exact and impersonal mechanism, in accordance with its specific qualities. Rather should we say that the market is a voting machine, whereon countless individuals register choices which are the product pa… read more...

Global Blood Therapeutics: What The Recent HOPE-KIDS 1 Data Foretells

via: SeekingAlpha at 2018-06-22 08:13:08:000

The market is not a weighing machine, on which the value of each issue is recorded by an exact and impersonal mechanism, in accordance with its specific qualities. Rather should we say that the market is a voting machine, whereon countless individuals register choices which are the product pa… read more...

Your Daily Pharma Scoop: Selecta Bio Reports Positive, Acceleron And Atara Moves Up On Positive Data

via: SeekingAlpha at 2018-06-18 08:00:00:000

Analysis Focus: SELB Selecta Biopharma ( SELB ) recently presented more data from Phase 2 clinical trial of its lead candidate SEL-212 (SVP-Rapamycin + pegsiticase) in chronic severe gout. In this trial 27 patients were inducted. 81% of the patient group had a clearly marked lower level… read more...

Your Daily Pharma Scoop: Selecta Bio Reports Positive, Acceleron And Atara Moves Up On Positive Data

via: SeekingAlpha at 2018-06-18 08:00:00:000

Analysis Focus: SELB Selecta Biopharma ( SELB ) recently presented more data from Phase 2 clinical trial of its lead candidate SEL-212 (SVP-Rapamycin + pegsiticase) in chronic severe gout. In this trial 27 patients were inducted. 81% of the patient group had a clearly marked lower level… read more...

Your Daily Pharma Scoop: Selecta Bio Reports Positive, Acceleron And Atara Moves Up On Positive Data

via: SeekingAlpha at 2018-06-18 08:00:00:000

Analysis Focus: SELB Selecta Biopharma ( SELB ) recently presented more data from Phase 2 clinical trial of its lead candidate SEL-212 (SVP-Rapamycin + pegsiticase) in chronic severe gout. In this trial 27 patients were inducted. 81% of the patient group had a clearly marked lower level… read more...

Global Blood Therapeutics: Buy Unwarranted Dip Ahead Of HOPE Readout

via: SeekingAlpha at 2018-06-16 10:37:21:000

Shares of Global Blood Therapeutics ( GBT ) were sliced by 15% after an interim update on phase 2a data in a pediatric population. Data did not compare favorably to the update that was provided at ASH in December. As a result, investors did not respond well. However, a closer look reveals the … read more...

Global Blood Therapeutics: Buy Unwarranted Dip Ahead Of HOPE Readout

via: SeekingAlpha at 2018-06-16 10:37:21:000

Shares of Global Blood Therapeutics ( GBT ) were sliced by 15% after an interim update on phase 2a data in a pediatric population. Data did not compare favorably to the update that was provided at ASH in December. As a result, investors did not respond well. However, a closer look reveals the … read more...

Midday Gainers / Losers (06/15/2018)

via: SeekingAlpha at 2018-06-15 12:36:26:000

Gainers: CLPS +34% . GOOS +27% . NDRA +24% . BAK +19% . TPIV +19% . VSTM +16% . CFRX +15% . NETE +14% . TCI +14% . NEWA +13% . More news on: CLPS, Inc, Canada Goose Holdings, Endra Life Sciences Inc, Stocks on the move, , Read more … read more...

GBT's voxelotor shows lower treatment effect in adolescents with SCD in mid-stage study; shares slip 4% premarket

via: SeekingAlpha at 2018-06-15 08:01:21:000

Global Blood Therapeutics (NASDAQ: GBT ) announces data from patients treated with the 900 mg dose of voxelotor in the ongoing HOPE-KIDS 1 Study, a Phase 2a open-label study in adolescents with sickle cell disease (SCD) at the European Hematology Association (EHA) Congress inStockhol… read more...

Clover's Weekly Leaflet

via: SeekingAlpha at 2018-06-11 01:51:24:000

We look back at the week that was and look forward to the week to come. Viking Therapeutics takes advantage of good times and raises once more Viking Therapeutics ( VKTX ) announced Thursday that they intend to raise an additional $65M at $9/share to advance their clinical pipeline… read more...

Clover's Weekly Leaflet

via: SeekingAlpha at 2018-06-11 01:51:24:000

We look back at the week that was and look forward to the week to come. Viking Therapeutics takes advantage of good times and raises once more Viking Therapeutics ( VKTX ) announced Thursday that they intend to raise an additional $65M at $9/share to advance their clinical pipeline… read more...

Clover's Weekly Leaflet

via: SeekingAlpha at 2018-06-11 01:51:24:000

We look back at the week that was and look forward to the week to come. Viking Therapeutics takes advantage of good times and raises once more Viking Therapeutics ( VKTX ) announced Thursday that they intend to raise an additional $65M at $9/share to advance their clinical pipeline… read more...

The Eleven: Viking Skyrockets, Global Blood Is Fueling

via: SeekingAlpha at 2018-06-04 01:02:05:000

The Eleven The Eleven is a biotechnology portfolio of eleven stocks we believe have significant upside within a six month to one-year timeframe based upon company fundamentals and upcoming catalysts with good risk/reward ratios. They are listed in a way to reflect top picks and risk toleran… read more...

The Eleven: Viking Skyrockets, Global Blood Is Fueling

via: SeekingAlpha at 2018-06-04 01:02:05:000

The Eleven The Eleven is a biotechnology portfolio of eleven stocks we believe have significant upside within a six month to one-year timeframe based upon company fundamentals and upcoming catalysts with good risk/reward ratios. They are listed in a way to reflect top picks and risk toleran… read more...

The Eleven: Viking Skyrockets, Global Blood Is Fueling

via: SeekingAlpha at 2018-06-04 01:02:05:000

The Eleven The Eleven is a biotechnology portfolio of eleven stocks we believe have significant upside within a six month to one-year timeframe based upon company fundamentals and upcoming catalysts with good risk/reward ratios. They are listed in a way to reflect top picks and risk toleran… read more...

CRISPR Therapeutics down 20% after hours on IND hold for sickle cell candidate CTX001

via: SeekingAlpha at 2018-05-30 17:16:25:000

CRISPR Therapeutics (NASDAQ: CRSP ) slumps 20% after hours on robust volume in response to its disclosure that the FDA has placed a clinical hold on its IND for sickle cell disease (SCD) gene therapy candidate CTX001. The suspension will be in effect pending the resolution of c… read more...

CRISPR Therapeutics down 20% after hours on IND hold for sickle cell candidate CTX001

via: SeekingAlpha at 2018-05-30 17:16:25:000

CRISPR Therapeutics (NASDAQ: CRSP ) slumps 20% after hours on robust volume in response to its disclosure that the FDA has placed a clinical hold on its IND for sickle cell disease (SCD) gene therapy candidate CTX001. The suspension will be in effect pending the resolution of c… read more...

CRISPR Therapeutics down 20% after hours on IND hold for sickle cell candidate CTX001

via: SeekingAlpha at 2018-05-30 17:16:25:000

CRISPR Therapeutics (NASDAQ: CRSP ) slumps 20% after hours on robust volume in response to its disclosure that the FDA has placed a clinical hold on its IND for sickle cell disease (SCD) gene therapy candidate CTX001. The suspension will be in effect pending the resolution of c… read more...

Learning From The Best - How Joseph Edelman (Perceptive Advisors) Invests

via: SeekingAlpha at 2018-05-30 01:59:54:000

This is intended to be an educative article, where I examine three successful investments made by Perceptive Advisors (at least successful to date), one of the biotech-focused hedge funds I value the most and look with interest what they are doing each quarter when they file their 13Fs with … read more...

Learning From The Best - How Joseph Edelman (Perceptive Advisors) Invests

via: SeekingAlpha at 2018-05-30 01:59:54:000

This is intended to be an educative article, where I examine three successful investments made by Perceptive Advisors (at least successful to date), one of the biotech-focused hedge funds I value the most and look with interest what they are doing each quarter when they file their 13Fs with … read more...

Learning From The Best - How Joseph Edelman (Perceptive Advisors) Invests

via: SeekingAlpha at 2018-05-30 01:59:54:000

This is intended to be an educative article, where I examine three successful investments made by Perceptive Advisors (at least successful to date), one of the biotech-focused hedge funds I value the most and look with interest what they are doing each quarter when they file their 13Fs with … read more...

Global Blood Therapeutics: Elucidating The Upcoming Clinical Binary

via: SeekingAlpha at 2018-05-25 03:37:05:000

Wall Street sometimes gets confused between risk and uncertainty, and you can profit handsomely from that confusion. The low-risk, high-uncertainty situation gives us our most sought after coin-toss odds. Heads, I win; tails, I don't lose much. - Mohnish Pabrai Global Blood Therapeutics … read more...

Global Blood Therapeutics: Elucidating The Upcoming Clinical Binary

via: SeekingAlpha at 2018-05-25 03:37:05:000

Wall Street sometimes gets confused between risk and uncertainty, and you can profit handsomely from that confusion. The low-risk, high-uncertainty situation gives us our most sought after coin-toss odds. Heads, I win; tails, I don't lose much. - Mohnish Pabrai Global Blood Therapeutics … read more...

Global Blood Therapeutics: Elucidating The Upcoming Clinical Binary

via: SeekingAlpha at 2018-05-25 03:37:05:000

Wall Street sometimes gets confused between risk and uncertainty, and you can profit handsomely from that confusion. The low-risk, high-uncertainty situation gives us our most sought after coin-toss odds. Heads, I win; tails, I don't lose much. - Mohnish Pabrai Global Blood Therapeutics … read more...

Global Blood Therapeutics: Elucidating The Upcoming Clinical Binary

via: SeekingAlpha at 2018-05-25 03:37:05:000

Wall Street sometimes gets confused between risk and uncertainty, and you can profit handsomely from that confusion. The low-risk, high-uncertainty situation gives us our most sought after coin-toss odds. Heads, I win; tails, I don't lose much. - Mohnish Pabrai Global Blood Therapeutics … read more...

Global Blood Therapeutics: Elucidating The Upcoming Clinical Binary

via: SeekingAlpha at 2018-05-25 03:37:05:000

Wall Street sometimes gets confused between risk and uncertainty, and you can profit handsomely from that confusion. The low-risk, high-uncertainty situation gives us our most sought after coin-toss odds. Heads, I win; tails, I don't lose much. - Mohnish Pabrai Global Blood Therapeutics … read more...

Global Blood Therapeutics: Elucidating The Upcoming Clinical Binary

via: SeekingAlpha at 2018-05-25 03:37:05:000

Wall Street sometimes gets confused between risk and uncertainty, and you can profit handsomely from that confusion. The low-risk, high-uncertainty situation gives us our most sought after coin-toss odds. Heads, I win; tails, I don't lose much. - Mohnish Pabrai Global Blood Therapeutics … read more...

Global Blood Therapeutics: Elucidating The Upcoming Clinical Binary

via: SeekingAlpha at 2018-05-25 03:37:05:000

Wall Street sometimes gets confused between risk and uncertainty, and you can profit handsomely from that confusion. The low-risk, high-uncertainty situation gives us our most sought after coin-toss odds. Heads, I win; tails, I don't lose much. - Mohnish Pabrai Global Blood Therapeutics … read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Global Blood Therapeutics: Potential To Enhance Blood Flow In Patients And Money Flow For Investors

via: SeekingAlpha at 2018-05-23 05:07:35:000

On October 25, 2017, I shared my first article for my SA readers dealing with Global Blood Therapeutics (GBT). At the time of that article, the stock was trading for $33.20 a share. I pointed out to my readers that the timing of the article was designed to make them aware of the major … read more...

Global Blood Therapeutics: Potential To Enhance Blood Flow In Patients And Money Flow For Investors

via: SeekingAlpha at 2018-05-23 05:07:35:000

On October 25, 2017, I shared my first article for my SA readers dealing with Global Blood Therapeutics (GBT). At the time of that article, the stock was trading for $33.20 a share. I pointed out to my readers that the timing of the article was designed to make them aware of the major … read more...

Global Blood Therapeutics: Potential To Enhance Blood Flow In Patients And Money Flow For Investors

via: SeekingAlpha at 2018-05-23 05:07:35:000

On October 25, 2017, I shared my first article for my SA readers dealing with Global Blood Therapeutics (GBT). At the time of that article, the stock was trading for $33.20 a share. I pointed out to my readers that the timing of the article was designed to make them aware of the major … read more...

Global Blood Therapeutics: Potential To Enhance Blood Flow In Patients And Money Flow For Investors

via: SeekingAlpha at 2018-05-23 05:07:35:000

On October 25, 2017, I shared my first article for my SA readers dealing with Global Blood Therapeutics (GBT). At the time of that article, the stock was trading for $33.20 a share. I pointed out to my readers that the timing of the article was designed to make them aware of the major … read more...

Lucky Seven: Bio Struggles, Achaogen Breaks Key Support

via: SeekingAlpha at 2018-05-21 23:22:11:000

Micron's ( MU ) raise before earnings and softened trade-war talk with China may have shifted money towards tech and away from biotech. Or, at least, it's nice to think that way. Not only did we see a sea of red, but we saw a member of the green boxes say, in capital letters, "EW". How rud… read more...

Lucky Seven: Bio Struggles, Achaogen Breaks Key Support

via: SeekingAlpha at 2018-05-21 23:22:11:000

Micron's ( MU ) raise before earnings and softened trade-war talk with China may have shifted money towards tech and away from biotech. Or, at least, it's nice to think that way. Not only did we see a sea of red, but we saw a member of the green boxes say, in capital letters, "EW". How rud… read more...

Lucky Seven: Exelixis Bounces Back, Global Blood Therapeutics Bleeds

via: SeekingAlpha at 2018-05-19 16:35:08:000

Lucky Seven The Lucky Seven is a swing-trading biotechnology portfolio of seven stocks listed in a way to reflect top picks and risk tolerance. The first three picks are the top picks (in no particular order). Risks are increased the further away a stock sits from #4 (the least risky st… read more...

Lucky Seven: Exelixis Bounces Back, Global Blood Therapeutics Bleeds

via: SeekingAlpha at 2018-05-19 16:35:08:000

Lucky Seven The Lucky Seven is a swing-trading biotechnology portfolio of seven stocks listed in a way to reflect top picks and risk tolerance. The first three picks are the top picks (in no particular order). Risks are increased the further away a stock sits from #4 (the least risky st… read more...

Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics

via: SeekingAlpha at 2018-05-16 03:55:30:000

Lucky Seven The Lucky Seven is a swing-trading biotechnology portfolio of seven stocks listed in a way to reflect top picks and risk tolerance. The first three picks are the top picks (in no particular order). Risks are increased the further away a stock sits from #4 (the least risky stoc… read more...

Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics

via: SeekingAlpha at 2018-05-16 03:55:30:000

Lucky Seven The Lucky Seven is a swing-trading biotechnology portfolio of seven stocks listed in a way to reflect top picks and risk tolerance. The first three picks are the top picks (in no particular order). Risks are increased the further away a stock sits from #4 (the least risky stoc… read more...

Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics

via: SeekingAlpha at 2018-05-16 03:55:30:000

Lucky Seven The Lucky Seven is a swing-trading biotechnology portfolio of seven stocks listed in a way to reflect top picks and risk tolerance. The first three picks are the top picks (in no particular order). Risks are increased the further away a stock sits from #4 (the least risky stoc… read more...

Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics

via: SeekingAlpha at 2018-05-16 03:55:30:000

Lucky Seven The Lucky Seven is a swing-trading biotechnology portfolio of seven stocks listed in a way to reflect top picks and risk tolerance. The first three picks are the top picks (in no particular order). Risks are increased the further away a stock sits from #4 (the least risky stoc… read more...

Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics

via: SeekingAlpha at 2018-05-16 03:55:30:000

Lucky Seven The Lucky Seven is a swing-trading biotechnology portfolio of seven stocks listed in a way to reflect top picks and risk tolerance. The first three picks are the top picks (in no particular order). Risks are increased the further away a stock sits from #4 (the least risky stoc… read more...

Lucky Seven: Achaogen Likely To Bounce Back

via: SeekingAlpha at 2018-05-14 08:19:53:000

The biotechnology sector ( XBI ) felt good about itself last week. As a result, many of the promising, up-and-coming biotechnology companies saw investors throwing their cash back at them in hopes of profitable returns. We anticipate the trend will continue, at least for a short time: C… read more...

Lucky Seven: Achaogen Likely To Bounce Back

via: SeekingAlpha at 2018-05-14 08:19:53:000

The biotechnology sector ( XBI ) felt good about itself last week. As a result, many of the promising, up-and-coming biotechnology companies saw investors throwing their cash back at them in hopes of profitable returns. We anticipate the trend will continue, at least for a short time: C… read more...

Lucky Seven: Achaogen Likely To Bounce Back

via: SeekingAlpha at 2018-05-14 08:19:53:000

The biotechnology sector ( XBI ) felt good about itself last week. As a result, many of the promising, up-and-coming biotechnology companies saw investors throwing their cash back at them in hopes of profitable returns. We anticipate the trend will continue, at least for a short time: C… read more...

Lucky Seven: Omeros Pops, Exelixis Drops On Phase 3 Flop

via: SeekingAlpha at 2018-05-12 00:23:51:000

Thursday and Friday were eventful days for the Lucky Seven and for biotechnology stocks, in general. It requires portfolio reassessment. First, Some Guidelines Before we begin, I'd like to discuss some additional key points to the purpose of the Lucky Seven portfolio: The goal, for all… read more...

Lucky Seven: Omeros Pops, Exelixis Drops On Phase 3 Flop

via: SeekingAlpha at 2018-05-12 00:23:51:000

Thursday and Friday were eventful days for the Lucky Seven and for biotechnology stocks, in general. It requires portfolio reassessment. First, Some Guidelines Before we begin, I'd like to discuss some additional key points to the purpose of the Lucky Seven portfolio: The goal, for all… read more...

Lucky Seven: Omeros Pops, Exelixis Drops On Phase 3 Flop

via: SeekingAlpha at 2018-05-12 00:23:51:000

Thursday and Friday were eventful days for the Lucky Seven and for biotechnology stocks, in general. It requires portfolio reassessment. First, Some Guidelines Before we begin, I'd like to discuss some additional key points to the purpose of the Lucky Seven portfolio: The goal, for all… read more...

2 Small Biotechs For The Rest Of 2018

via: SeekingAlpha at 2018-05-11 12:39:00:000

"Don't waste your time with explanations: people only hear what they want to hear." - Paulo Coelho Today, we profile two small biotech stocks that are set up to do very well for the rest of 2018. Both seem to be buys at current trading levels either via accumulation or via buy-write order… read more...

2 Small Biotechs For The Rest Of 2018

via: SeekingAlpha at 2018-05-11 12:39:00:000

"Don't waste your time with explanations: people only hear what they want to hear." - Paulo Coelho Today, we profile two small biotech stocks that are set up to do very well for the rest of 2018. Both seem to be buys at current trading levels either via accumulation or via buy-write order… read more...

Rounds Report: Global Blood Therapeutics Rallied While Improving FDA Policies To Help Nektar

via: SeekingAlpha at 2018-05-10 02:38:14:000

Acquire worldly wisdom and adjust your behavior accordingly. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for May 09, 2018. As usual, well elucidate notable trading analytics for the day, recent insider transactions, and interesti… read more...

Rounds Report: Global Blood Therapeutics Rallied While Improving FDA Policies To Help Nektar

via: SeekingAlpha at 2018-05-10 02:38:14:000

Acquire worldly wisdom and adjust your behavior accordingly. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for May 09, 2018. As usual, well elucidate notable trading analytics for the day, recent insider transactions, and interesti… read more...

Lucky Seven: Omeros Moves, Array Biopharma May Be Next

via: SeekingAlpha at 2018-05-08 15:02:53:000

iShares Nasdaq Biotechnology ETF ( IBB ) was good for a 0.3% gain within the last three trading days, while the Lucky Seven netted a 2.6% gain. The Lucky Seven portfolio assumes an investor made a $1000 investment, to begin, in each pick. So, the portfolio began with $7,000. Lucky Seven … read more...

Lucky Seven: Omeros Moves, Array Biopharma May Be Next

via: SeekingAlpha at 2018-05-08 15:02:53:000

iShares Nasdaq Biotechnology ETF ( IBB ) was good for a 0.3% gain within the last three trading days, while the Lucky Seven netted a 2.6% gain. The Lucky Seven portfolio assumes an investor made a $1000 investment, to begin, in each pick. So, the portfolio began with $7,000. Lucky Seven … read more...

Lucky Seven: An Introduction To My Top Biotechnology Picks

via: SeekingAlpha at 2018-05-03 05:28:00:000

Introduction I am a Registered Nurse, currently advancing my education at Purdue University. I work on an intermediate care unit in a hospital where I am responsible for the care and lives of folks who come to me with a myriad of medical conditions. I hope to soon become a nursing professor…. read more...

Global Blood Therapeutics: The Anatomy Of A Senseless Drop

via: SeekingAlpha at 2018-04-30 02:20:03:000

Since I presented an investment in Global Blood Therapeutics ( GBT ) as a Grade 'A' opportunity in January, the stock has dropped 20%. In fact, since it rode a cloud after receiving Breakthrough Therapy Designation (BTD) for voxelotor, it has fallen in excess of 30% from its greatest heigh… read more...

Global Blood Therapeutics (GBT) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow

via: SeekingAlpha at 2018-04-11 13:17:48:000

The following slide deck was published by Global Blood Therapeutics in conjunction with this Read more … read more...

Biotechs Approaching New Waters

via: SeekingAlpha at 2018-03-20 12:01:06:000

Biotech Pulse Biotech stocks are now approaching the highs experienced in mid-2015. The extended consolidation period of 2 1/2 years has set up biotechs for a prolonged rally as it approaches the point of eclipsing the all-time high achieved in 2015. The Nasdaq Biotechnology Index, as repr… read more...

ROTY Edition 1 Volume 78: Simplify Your Decision-Making And Stick To Guidelines

via: SeekingAlpha at 2018-02-13 12:46:16:000

Welcome to the 78th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React

via: SeekingAlpha at 2018-02-09 07:54:39:000

Welcome to the 77th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React

via: SeekingAlpha at 2018-02-09 07:54:39:000

Welcome to the 77th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React

via: SeekingAlpha at 2018-02-09 07:54:39:000

Welcome to the 77th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React

via: SeekingAlpha at 2018-02-09 07:54:39:000

Welcome to the 77th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React

via: SeekingAlpha at 2018-02-09 07:54:39:000

Welcome to the 77th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 76: How To Deal With Market Selloffs And Spring Cleaning For The Contenders List

via: SeekingAlpha at 2018-02-06 11:42:23:000

Welcome to the 76th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 75: The Future Of ROTY, Cascadian Acquired And Updates

via: SeekingAlpha at 2018-02-02 10:50:57:000

Welcome to the 75th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 75: The Future Of ROTY, Cascadian Acquired And Updates

via: SeekingAlpha at 2018-02-02 10:50:57:000

Welcome to the 75th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 75: The Future Of ROTY, Cascadian Acquired And Updates

via: SeekingAlpha at 2018-02-02 10:50:57:000

Welcome to the 75th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 75: The Future Of ROTY, Cascadian Acquired And Updates

via: SeekingAlpha at 2018-02-02 10:50:57:000

Welcome to the 75th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 74: A New Feature For Readers, Updates And Trades

via: SeekingAlpha at 2018-01-30 11:51:02:000

Welcome to the 74th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 74: A New Feature For Readers, Updates And Trades

via: SeekingAlpha at 2018-01-30 11:51:02:000

Welcome to the 74th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 74: A New Feature For Readers, Updates And Trades

via: SeekingAlpha at 2018-01-30 11:51:02:000

Welcome to the 74th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

ROTY Edition 1 Volume 73: New Features And A Controversial Swap Out

via: SeekingAlpha at 2018-01-25 06:21:35:000

Welcome to the 73rd entry in our Runner of the Year ((ROTY)) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primar… read more...

ROTY Edition 1 Volume 73: New Features And A Controversial Swap Out

via: SeekingAlpha at 2018-01-25 06:21:35:000

Welcome to the 73rd entry in our Runner of the Year ((ROTY)) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primar… read more...

ROTY Edition 1 Volume 72: Biotech Shines In January As We Manage Risk Appropriately

via: SeekingAlpha at 2018-01-23 13:23:39:000

Welcome to the 72nd entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-23 08:46:56:000

Abeona Therapeutics (NASDAQ: ABEO ) initiated with Outperform rating and $26 (75% upside) price target by RBC Capital. More news on: Abeona Therapeutics Inc., Global Blood Therapeutics, Amgen Inc., Healthcare stocks news, Read more … read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: January 16, 2018

via: SeekingAlpha at 2018-01-17 03:07:27:000

Market and sector outlook There was a sharp pullback in the U.S. market indexes due to fear of government shutdown. VIX was up more than 14% (after being up 21% at one time). Expect more volatility. U.S. biotech indexes were down with the rest of the market. The sector has a higher beta … read more...

ROTY Edition 1 Volume 70: A Solid Start To January And Thoughts On Taking Profits

via: SeekingAlpha at 2018-01-16 12:34:36:000

Welcome to the 70th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

Biotech Daily Digest For January 16th

via: SeekingAlpha at 2018-01-16 08:48:53:000

It's the fine balance of caffeine and alcohol that bookends my days Tim Minchin While biotech has risen in 2018, its performance YTD lags behind other sectors that will be more immediate beneficiaries of the recently passed tax reform legislation. These include domestica… read more...

Global Blood Therapeutics: What The Recent FDA Breakthrough Therapy Designation For Voxelotor Entails

via: SeekingAlpha at 2018-01-14 02:21:07:000

Time is on your side when you own shares of superior companies. - Peter Lynch For the past 5 days, the share price of Global Blood Therapeutics (NASDAQ: GBT ), a firm focusing on the development of medicine to service sickle cell disease, traded up by $15.1 at $56.55 (for 36% gains). In … read more...

Your Daily Pharma Scoop: Lipocine's Gloomy Future, Puma Labeling Change, Concert's Mixed Day

via: SeekingAlpha at 2018-01-13 08:00:00:000

Today we will discuss the Ad Com's vote against Lipocine's ( LPCN ) TLANDO. The news sparked a huge sell-off in LPCN on Wednesday. Few days before the Ad Com, we had written a note on LPCN, highlighting that it is a binary event. TLANDO had been rejected by the FDA in 2016, which pushed LPCN… read more...

Global Blood Therapeutics: Grade 'A' Opportunity

via: SeekingAlpha at 2018-01-11 09:42:21:000

Just days after an article of mine detailed the risks and potential downside associated with an investment in Global Blood Therapeutics (NASDAQ: GBT ), shares of GBT fell by over 20% on the heels of concerns over voxelotor-treated patient deaths and a $100 million public offering that fo… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud